E28 Literaturhinweise und Internetadressen - Elsevier.de · E28 Literaturhinweise und...

e1

© Elsevier GmbH, München 2015. Possinger, Regierer: Facharztwissen Hämatologie Onkologie, 3. Aufl age

E28 Literaturhinweise und Internetadressen

Literaturhinweise und Internetadressene2


1 Internistische TumortherapieBerenson JR et al. Long-term pamidronate treatment of advanced multiple myelo-ma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16 (2) (1998) 593–602.

Body JJ et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16 (12) (1998) 3890–3899.

Hillner BE et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphos-phonates Expert Panel. J Clin Oncol 18 (6) (2000) 1378–1391.

Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of pre-defi ned specifi city. Nature 256 (5517) (1975) 495–497.

Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 24 (5) (2001) 392–407.

Loppnow H. Cytokines: classifi cation, receptors, mechanisms of action. Internist 42 (1) (2001) 13–14, 17–27.

Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 24 (5) (2001) 392–407.

Possinger K, Schmid P. Supportivbehandlung von Knochenmetastasen. Uni-MED, Bremen 2002.

Schmoll H-J, Höff ken K, Possinger K (Hrsg.). Kompendium Internistische Onkolo-gie, Band 3, Kap. 30, Springer, Berlin (1999)

Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice gui-deline. J Clin Oncol. 24 (2006) 3187–3205.

Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7 (1989) 601–624.

2 Supportive Therapie

2.1 AntiemeseGrunberg SM, Osoba D, Hesketh PJ et al. Evaluation of new antiemetic agents and defi nition of antineoplastic agent emetogenicity – an update. Support Care Cancer 31 (2) (2005) 80–84.

Koeller JM, Aapro MS, Gralla RJ et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 10 (7) (2002) 519–522.

Roila F et al. Guideline update for MASCC and ESMO in the prevention of chemo-therapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol 21 Suppl 5 (2010) v232–v243.

Schmoll HJ, Höff ken K, Possinger K. Kompendium internistische Onkologie. Springer, Berlin 1999.

e32 Supportive Therapie


2.2 SchmerztherapieBaron R. Neuropathische Schmerzen: Der lange Weg vom Mechanismus zur me-chanismen-orientierten Therapie. Anästhesist 7 (2000) 120–131.

McQuay H. Opioids in pain management. Lancet 353 (1999) 2229–2232.

Therapieempfehlungen der Arzneimittelkommission der deutschen Ärzteschaft, 2. Aufl age 2000. AVP-Sonderheft, Köln 2000.

2.3 SubstitutionstherapieQuerschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderi-vaten, 4. Aufl age 2008 (www.aerztekammer.de).

2.4 Maligne ErgüsseFrampton JE. Catumaxomab: in malignant ascites. Drugs 72 (10) (2012) 1399–1410.

West SD, Davies RJ, Lee YC. Pleurodesis for malignant pleural eff usions: current controversies and variations in practices. Curr Opin Pulm Med 10 (4) (2004) 305–310.

2.5 Psychoonkologie und psychiatrische Störungen bei Krebskranken

Angelino AF, Treisman GJ. Major depression and demoralization in cancer pati-ents: diagnostic and treatment considerations. Support Care Cancer 9 (2001) 344–349.

Block SD. Psychological considerations, growth, and transcendence at the end of life. JAMA 285 (2001) 2898–2905.

Bower JE. Behavioral Symptoms in Patients With Breast Cancer and Survivors. J Clin Oncol 26 (2008) 768–777.

Breitbart W, Alici Y. Evidence-Based Treatment of Delirium in Patients with Can-cer. J Clin Oncol 30 (2012) 1206–1214.

Fitzgerald P, Rodin G. Evidence-Based Treatment of Depression in Patients with Cancer. J Clin Oncol 30 (2012) 1187–1196.

Lawlor PG et al. Occurrence, Courses and Outcome of Delirium in Patients with Cancer. Arch Intern Med 160 (2000) 786–794.

Traeger L et al. Evidence-Based Treatment of Anxiety in Patients With Cancer. J Clin Oncol 30 (2012) 1206–1214.

2.6 Fertilitätserhaltende MaßnahmenBedaiwy MA et al. Gonadotropin-releasing hormone analog cotreatment for pre-servation of ovarian function during gonadotoxic chemotherapy: A systematic re-view and meta-analysis. Fertil Steril 95 (2011) 906–914.



Behringer K et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 21 (2010) 2052–2060.

Gerber B et al. Eff ect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study. J Clin Oncol 29 (2011) 2334–2341.

Wolff M von, Dian D. Fertilitätsprotektion bei Malignomen und gonadotoxischen Therapien. Dtsch Arztebl Int 109 (12) (2012) 220–226.

Wolff H, Pesic K. Manual Supportive Maßnahmen und symptomorientierte Thera-pie. Maßnahmen zur Erhaltung der Fertilität bei Männern. Tumorzentrum Mün-chen 2001.

www.fertiprotekt.de

3 StammzelltransplantationAversa F, Terenzi A, Tabilio A et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447–3454.

Barker JN. Umbilical Cord Blood (UCB) transplantation: an alternative to the use of unrelated volunteer donors? Hematology Am Soc Hematol Educ Program (2007) 55–61.

Bensinger W, Martin P, Storer B et al. Transplantation of bone marrow as compa-red with peripheral-blood cells from HLA-identical relatives in patients with hema-tologic cancers. N Engl J Med 344 (2001) 175–181.

Eapen M, Logaan BR, Confer D et al. Peripheral blood grafts from unrelated do-nors are associated with increased acute and chronic graft-versus-host disease wit-hout improved survival. Biol Blood Marrow Transplant 13 (2007) 1461–1468.

Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562.

Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treat-ment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 (1990) 2462–2465.

Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103 (2004) 767–776.

Larghero J, Garcia J, Gluckman E. Sources and procurement of stem cells. In: Ap-perley J, Carreras E, Gluckman E, Gratwohl A, Maszi T, (eds.). The EBMT Hand-book. Haematopoietic Stem Cell Transplantation. Paris 2008. 112–127.

Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825–828.

Rocha V, Labopin M, Sanz GF. Transplants of umbilical cord blood or bone mar-row from unrelated donors in adults with acute leukaemia. N Engl J Med 351 (2004) 2276–2285.

e54 Infektionen bei Patienten mit hämatologisch-onkologischen Erkrankungen


Schmid C, Labopin M, Nagler A et al. Donor lymphocyte infusion in the treatment of fi rst hematological relapse after allogeneic stem cell transplantation in adults with acute myeloid leukaemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working. J Clin Oncol 25 (2007) 4938–4945.

Schmitz N, Beksac M, Hasenclever D et al. Transplantation of mobilized periphe-ral blood cells to HLA identical siblings with standard-risk leukemia. Blood 100 (2002) 761–767.

Schrezenmeier H, Passweg J, Marsh J et al. Worse outcome and more chronic Gv-HD with peripheral blood progenitor cells than bone marrowin HLA-matched sib-ling donor transplants for young patients with severe acquired aplsatic anemia. Blood 110 (2007) 1397–1400.

Sorror ML, Maris M, Storb R et al. Hematopoietic cell transplantation (HCT)-specifi c comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005) 2912–2919.

Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leu-kemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell‘Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332 (1995) 217–223.

4 Infektionen bei Patienten mit hämatologisch-onkologischen Erkrankungen

Bertz H, Auner HW, Weissinger F et al. Antimicrobial therapy of febrile complica-tions after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82 (Sup-pl 2) (2003) S167–174.

Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64 (1966) 328–340

Böhme A, Ruhnke M, Buchheidt D et al. Treatment of fungal infections in hemato-logy and oncology – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82 (Suppl 2) (2003) S133–140.

Buchheidt D, Boehme A, Cornely OA et al. Diagnosis and treatment of documented infections in neutropenic patients – recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82 (Suppl 2) (2003) S127–132.

Cornely OA, Bohme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M et al. Pri-mary prophylaxis of invasive fungal infections in patients with hematologic malig-nancies. Recommendations of the Infectious Diseases Working Party of the Ger-man Society for Haematology and Oncology. Haematologica 94 (1) (2009) 113–122.



Crawford J, Caserta C, Roila F et al. Hematopoietic growth factors: ESMO Clini-cal Practice Guidelines for the applications. Ann Oncol 21 (suppl 5) (2010) v248–v251.

de Naurois J, Novitzky-Basso I, Gill MJ et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 21 (suppl 5) (2010) v252–v256.

Einsele H, Bertz H, Beyer J et al. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hemato-logy and Oncology (DGHO). Ann Hematol 82 (Suppl 2) (2003) S175–185.

Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infec-tious Diseases Society of America. Clin Infect Dis 52 (4) (2011) e56–e93.

Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimi-crobial agents in neutropenic patients with cancer. Clin Infect Dis 34 (2002) 730–751.

Kern WV, Beyer J, Böhme A et al. Infektionsprophylaxe bei neutropenischen Pati-enten – Leitlinien der Arbeitsgemeinschaft Infektionen in der Haematologie und Onkologie. Dtsch Med Wochenschr 125 (2000) 1582.

Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identify-ing low-risk febrile neutropenic cancer patients. J Clin Oncol 18 (2000) 3038–3051.

Kruger WH, Bohlius J, Cornely OA et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the german society of haematology and oncology. Ann Oncol 16 (8) (2005) 1381–1390.

Link H, Böhme A, Cornely O et al. Antimicrobial therapy of unexplained fever in neutropenic patients – guidelines of the Infectious Diseases Working Party (AGI-HO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmaß-nahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 82 (Suppl 2) (2003) S105–117.

Maschmeyer G, Link H, Hiddemann W et al. Empirical antimicrobial therapy in neutropenic patients. Results of a multicenter study by the Infections in Hematolo-gy Study Group of the Paul Ehrlich Society. Med Klin 89 (1994) 114–123.

Mousset S, Buchheidt D, Heinz W et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Par-ty (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 93 (1) (2014) 13–32.

Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in pati-ents with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and On-cology (DGHO). Ann Hematol 92 (4) (2013) 433–442.

Ruhnke M, Böhme A, Buchheidt D et al. Diagnosis of invasive fungal infections in hematology and oncology – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann He-matol 82 (Suppl 2) (2003) S141–S148.

e76 Anämien


Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epide-miology of nosocomial bloodstream infections in patients with hematological mali-gnancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36 (2003) 1103.

Internetadressenhttp://www.dgho-infektionen.de/agiho/content

http://www.idsociety.org

http://www.ichs.org

5 Tumor- und therapieassoziierte NotfälleMader I, Fürst-Weger PR, Mader RM et al. Paravasation von Zytostatika. Sprin-ger, Wien–New York 2002.

Witte J, de Wit M. Was tun wenn’s brennt. Im Fokus Onkologie 6 (2010) 50–55.

http://www.onkosupport.de

6 AnämienAhmad A, Aggarwal A, Schechter GP et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 77 (2004) 171–176.

Auerbach M, Ballard H. Clinical Use of Intravenous Iron: Administration, Effi cacy, and Safety. Am Soc Hematol Educ Program 2010 (2010) 338–347.

Gisbert JP, Gomollon F. Classifi cation of anemia for gastroenterologist. World J Gastroenterol 15 (2009) 4627–4637.

Green R. Anemias beyond B12 and iron defi ciency: the buzz about other elementary B´s and nomelementary problems. Hematology Am Soc Hematol Educ Program 2012 (2012) 492–498.

Koury MJ, Rhodes M. How to approach chronic anemia. Hematology Am Soc Hematol Educ Program 2012 (2012) 183–190.

Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults. Blood 16 (2010) 1831–1838.

Pu JJ, BrodskyRA. Paroxysmal Nocturnal Hemoglobinuria from Bench to Bedside. Clin Transl Sci 4 (2011) 219–224.

Solomon L. Cobalamin-responsive disorders in the ambulatory care setting: unreli-ability of cobalamin, methylmalonic acid, and homocysteine testing. Blood 105 (2005) 978–85.



7 Aplastische AnämienBacigalupo A, Locatelli F, Lanino E et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (SAA WP-EBMT). Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Wor-king Party. Bone Marrow Transplant 36 (2005) 947–950.

Bacigalupo A, Socié G, Lanino E et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (SAA WP-EBMT). Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica 95 (2010) 976–982.

Bacigalupo A, Socié G, Schrezenmeier H et al. Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (WPSAA-EBMT). Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica 97 (2012) 1142–1148.

Deeg HJ, O‘Donnell M, Tolar J et al. Optimization of conditioning for marrow trans-plantation from unrelated donors for patients with aplastic anemia after fai-lure of immunosuppressive therapy. Blood 108 (2006) 1485–1491.

Dokal I, Vulliamy T. Inherited bone marrow failure syndromes. Haematologica 95 (2010) 1236–1240.

Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globu-lin with or without cyclosporin A: 11-year follow-up of a randomized trial compa-ring treatments of aplastic anemia. Blood 101 (2003) 1236–1242.

Gandhi S, Kulasekararaj AG, Mufti GJ, Marsh JC. Allogeneic stem cell transplan-tation using alemtuzumab-containing regimens in severe aplastic anemia. Int J He-matol 97 (2013) 573–580.

Hamad N, Del Bel R, Messner HA, et al. Outcomes of hematopoietic cell trans-plantation in adult patients with acquired aplastic anemia using intermediate dose alemtuzumab-based conditioning. Biol Blood Marrow Transplant (2014) [Epub ahead of print].

Heimpel H. When should the clinician suspect a blood dyscrasia, and how should he proceed? Eur J Haematol 57 (1996) 11–15.

Horowitz MM. Current status of allogeneic bone marrow transplantation in acqui-red aplastic anemia. Semin Hematol 37 (2000) 30–42.

Marsh J for the EBMT SAA Working Party. Rabbit ATG for aplastic anaemia treatment: a backward step? The Lancet 378 (2011) 1831–1833.

Maury S, Bacigalupo A, Anderlini P et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fl udarabine-based conditioning: a compa-rison with conventional conditioning regimen. Haematologica 94 (2009) 1312–1315.

Olnes MJ, Scheinberg P, Calvo KR et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 376 (2012) 11–19.

e98 Akute Leukämien


Scheinberg P, Nunez O, Weinstein B et al. Horse versus rabbit antithymocyte glo-bulin in acquired aplastic anemia. N Engl J Med 365 (2011) 430–438.

Schrezenmeier H, Brümmendorf T, Linkesch W et al. Aplastische Anämie – Dia-gnostik und Therapie der erworbenen Aplastischen Anämie. Onkopedia Leitlinie Mai 2012.

Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymo-cyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 84 (1994) 941–949.

Tichelli A, Socie G, Henry-Amar M et al. Eff ectiveness of immunosuppressive the-rapy in older patients with aplastic anemia. European Group for Blood and Mar-row Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med 130 (1999) 193–201.

Internetadressenhttp://www.dgho.de (Therapieempfehlungen der DGHO)

http://www.aplastische-anaemie.com (Deutsche Studiengruppe Aplastische Anä-mie)

http://www.ebmt.org/Contents/Research/EBMTStudies/CurrentResearch/Pages/CurrentResearch.aspx (Aplastic Anaemia Working Party der EBMT)

http://www.aamds-international.org (Aplastic Anemia International Foundation)

http://www.aplastische-anaemie.de (Aplastische Anämie e. V.)

7.2 Isolierte aplastische AnämieBennett CL, Luminari S, Nissenson AR et al. Pure red-cell aplasia and epoetin the-rapy. N Engl J Med 351 (2004) 1403–1408.

Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood 87 (1996) 4831–4838.

Clark DA, Dessypris EN, Krantz SB. Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood 63 (1984) 277–286.

Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 72 (2004) 79–88.

8 Akute LeukämienAdès L, Sanz MA, Chevret S et al. Treatment of newly diagnosed acute promyelo-cytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA re-sults. Blood 111 (3) (2008) 1078–1084.

Bassan R and Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 29 (5) (2011) 532–543.

Bene MC, Bernier M, Casasnovas RO et al. The reliability and specifi city of c-kit for the diagnosis of acute myeloid leukemias and undiff erentiated leukemias. The



European Group for the Immunological Classifi cation of Leukemias (EGIL). Blood 92 (2) (1998) 596–599.

Bene MC, Castoldi G, Knapp W et al. Proposals for the immunological classifi ca-tion of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9 (10) (1995) 1783–1786.

Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classifi cation of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haema-tol 33 (4) (1976) 451–458.

Byrd JC, Mrozek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survi-val in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (13) (2002) 4325–4336.

Döhner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendationsfrom an international expert panel, on behalf of the European LeukemiaNet. Blood 115 (3) (2010) 453–474.

Hahn T, Wall D, Camitta B et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 12 (1) (2006) 1–30.

Hellenbrecht A, Messerer D, Gokbuget N. Häufi gkeit von Leukämien bei Erwach-senen in Deutschland (2008) Auf: www.kompetenznetz-leukaemie.de/content/aerz-te/epidemiologie/leukaemiehaeufi gkeit/index_ger.html (letzter Zugriff : 10.07.2014)

Huguet F; Leguay T, Raff oux E et al. Pediatric-inspired therapy in adults with Phi-ladelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 27 (2009) 911–918.

Kern W, Haferlach T, Schoch C et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the Ger-man AML Cooperative Group (AMLCG) 1992 Trial. Blood 101 (1) (2003) 64–70.

Killick S, Matutes E, Powles RL et al. Outcome of biphenotypic acute leukemia. Haematologica 84 (8) (1999) 699–706.

Larson RA, Dodge RK, Linker CA et al. A randomized controlled trial of fi lgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 92 (5) (1998) 1556–1564.

Leone G, Mele L, Pulsoni A et al. The incidence of secondary leukemias. Haemato-logica 84 (10) (1999) 937–945.

Lo-Coco F, Avvisati G, Vignetti M et al. Retinoic acid and arsenic trioxide for acu-te promyelocytic leukemia. N Engl J Med 369 (2) (2013) 111–121.

Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leuke-mia. Blood 121 (1) (2013) 26–28.

Mayer RJ, Davis RB, Schiff er CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331 (14) (1994) 896–903.

Pfi rrmann M, Ehninger G, Thiede C et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol 13 (2) (2012): 207–214.

e119 Myelodysplastische Syndrome (MDS)


Platzbecker U, Thiede C, Füssel M et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive in-duction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 20 (4) (2006) 707–714.

Repp R, Schaekel U, Helm G et al. Immunophenotyping is an independent factor for risk stratifi cation in AML. Cytometry 53B (1) (2003) 11–19.

Schaich M, Parmentier S, Kramer M et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: re-sults of the prospective randomized AML2003 trial. J Clin Oncol 31 (17) (2013) 2094–102.

Schaich M, Soucek S, Thiede C et al. MDR1 and MRP1 gene expression are inde-pendent predictors for treatment outcome in adult myeloid leukaemia. Br J Haema-tol 128 (3) (2005) 324–332.

Schetelig J, Bornhäuser M, Schmid C et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative Ger-man Transplant Study Group. J Clin Oncol 26 (32) (2008) 5183–5191.

Schlenk RF, Döhner K, Krauter J et al. Mutations and treatment outcome in cyto-genetically normal acute myeloid leukemia. N Engl J Med 358 (18) (2008) 1909–1918.

Thiede C, Steudel C, Mohr B et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identifi cation of subgroups with poor prognosis. Blood 99 (12) (2002) 4326–4335.

Usvasalo A, Raty R, Knuutila S et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica 93 (2008) 1161–1168.

Wandt H, Frank M, Ehninger G et al. Safety and cost eff ectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91 (10) (1998) 3601–3606.

World Health Organization Classifi cation of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2008.

9 Myelodysplastische Syndrome (MDS)Aul C, Gattermann N, Heyll A et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6 (1992) 52–59.

Bejar R. Prognostic models in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2013 (2013) 504–510.

Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classifi cation of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189–199.

Bennett JM, Catovsky D, Daniel TM et al. The chronic myeloid leukaemias: guide-lines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic



myelomonocytic leukaemia. Proposals by the French-American-British Cooperati-ve Leukaemia Group. Br J Haematol 78 (1994) 746–754.

Cheson BD, Bennett JM, Kantarjian H et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96 (2000) 3671–3674.

Cutler CS, Lee SJ, Greenberg P et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104 (2004) 579–585.

Daskalakis M, Nguyen TT, Nguyen C et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2‘-deoxycyti-dine (decitabine) treatment. Blood 100 (2002) 2957–2964.

de Witte T, Suciu S, Verhoef G et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndro-mes (MDSs) and acute myeloid leukemia following MDS. Blood 98 (2001) 2326–2331.

Deeg HJ, Shulman HM, Anderson JE et al. Allogeneic and syngeneic marrow trans-plantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95 (2000) 1188–1194.

Germing U, Gattermann N, Strupp C et al. Validation of the WHO proposals for a new classifi cation of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24 (2000) 983–992.

Germing U, Hildebrandt B, Pfeilstocker M et al. Refi nement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic va-riable to improve risk assessment in patients with primary myelodysplastic syndro-mes (MDS). Leukemia (12) (2005) 2223–2231.

Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndro-mes. Int J Hematol 73 (2001) 429–437.

Fenaux P Mufti GJ Hellstrom-Lindberg E et al. International Vidaza High-Risk MDS Survival Study Group. Effi cacy of azacitidine compared with that of conven-tional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (3) (2009) 223–232.

Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079–2088.

Greenberg PL, Tüchler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120 (2012) 2454–2465.

Hellström-Lindberg E, Negrin R, Stein R et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99 (1997) 344–351.

Kuendgen A, Strupp C, Aivado M et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104 (2004) 1266–1269.

List A, Dewald G, Bennett J et al. Myelodysplastic Syndrome-003 Study Investiga-tors. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355(14) (2006) 1456–1465.

e1310 Chronische myeloproliferative Neoplasien (CMPN)


List A, Kurtin S, Roe DJ et al. Effi cacy of lenalidomide in myelodysplastic syndro-mes. N Engl J Med 352 (2005) 549–557.

Malcovati L, Porte MG, Pascutto C et al. Prognostic factors and life expectancy in myelodysplastic syndromes classifi ed according to WHO criteria: a basis for clini-cal decision making. J Clin Oncol (2005) 23(30) 7594–7603.

Raza A, Qawi H, Lisak L et al. Patients with myelodysplastic syndromes benefi t from palliative therapy with amifostine, pentoxifylline, and ciprofl oxacin with or without dexamethasone. Blood 95 (2000) 1580–1587.

Schanz J, Tüchler H, Solé F et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leu-kemia after MDS derived from an international database merge. J Clin Oncol 30 (8) (2012) 820–829.

Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of aza-citidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (2002) 2429–2440.

Internetadressenhttp://www.mds-foundation.org (MDS-Foundation)

http://www.dgho-onkopedia.de/de/onkopedia/leitlinien/mds (MDS-Leitlinien)

http://www.mds-register.de/mdsstudien

http://www.kompetenznetz-leukaemie.de/content/aerzte/studien/studienregister/index_ger.html

10 Chronische myeloproliferative Neoplasien (CMPN)

Apperley JF, Gardembas M, Melo JV et al. Response to imatinib mesylate in pati-ents with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347 (2002) 481–487.

Baccarani M, Deininger MW, Rosti G et al. European LeukemiaNet recommenda-tions for the management of chronic myeloid leukemia: 2013. Blood. 122 (2013) 872–884.

Bachleitner-Hofmann T, Gisslinger H. The role of interferon-α in the treatment of idiopathic myelofi brosis. Ann Hematol 78 (1999) 533–538.

Barbui T, Barosi G, Birgegard G et al. Philadelphia-negative classical myeloprolife-rative neoplasms: critical concepts and management recommendations from Euro-pean LeukemiaNet. J Clin Oncol 29 (2011) 761–770.

Barosi G. Myelofi brosis with myeloid metaplasia. Hematol Oncol Clin N Am 17 (2003) 1211–1226.

Bonifazi F, de Vivo A, Rosti G et al. Chronic myeloid leukemia and α-Interferon. A study of complete cytogenetic responders. Blood 98 (2001) 3074–3081.

Burchert A, Müller MC, Kostrewa P et al. Sustained molecular response with inter-feron alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 28 (2010) 1429–1435.



Cervantes F, Dupriez B, Pereira A et al. New prognostic scoring system for primary myelofi brosis based on a study of the International Working Group for Myelofi bro-sis Research and Treatment. Blood 113 (2009) 2895–2901.

Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hyper-eosinophilic syndrome. N Engl J Med 348 (2003) 1201–1214.

Cortes JE, Kantarjian HM, Brümmendorf TH et al. Safety and effi cacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leu-kemia patients with resistance or intolerance to imatinib. Blood. 118 (2011) 4567–4576.

Cortes JE, Kim DW, Pinilla-Ibarz J et al. A phase 2 trial of ponatinib in Philadel-phia chromosome-positive leukemias. N Engl J Med 369 (2013) 1783–1796.

Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized defi nitions of molecular response in chronic myeloid leukemia. Leukemia 26 (2012) 2172–2175.

Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specifi c inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 (2001a) 1038–1042.

Druker BJ, Talpaz M, Resta DJ et al. Effi cacy and safety of a specifi c inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001b) 1031–1037.

Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 352 (1998) 1087–1092

Giles FJ, Mauro MJ, Hong F et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 27 (2013) 1310–1315.

Hanfstein B, Müller MC, Hehlmann R et al. Early molecular and cytogenetic res-ponse is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26 (2012) 2096–2102.

Harrison CN, Green AR. Essential thrombocythemia. Hematol Oncol Clin N Am 17 (2003) 1175–1190.

Harrison C, Kiladjian JJ, Al-Ali HK et al. JAK inhibition with ruxolitinib versus best available therapy for myelofi brosis. N Engl J Med 366 (2012) 787–798.

Hasford J, Baccarani M, Hoff mann V et al. Predicting complete cytogenetic respon-se and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118 (2011) 686–692.

Hasford J, Pfi rrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 90 (1998) 850–858.

Hehlmann R. How I treat CML blast crisis. Blood 120 (2012) 737–747.

Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The Ger-man CML Study Group. Blood 84 (1994) 4064–4077.

e1510 Chronische myeloproliferative Neoplasien (CMPN)


Hehlmann R, Hochhaus A, Kolb HJ et al. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not aff ect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 94 (1999) 3668–3677.

Hehlmann R, Lauseker M, Jung-Munkwitz S. Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-{alpha} in Newly Diag-nosed Chronic Myeloid Leukemia. J Clin Oncol 29 (2011) 1634–1642.

Hochhaus A, Kantarjian H. The development of dasatinib as a treatment for chro-nic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol. 139 (2013) 1971–1984.

Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190–2196.

Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: stra-tegies to avoid and overcome resistance. Leukemia 18 (2004) 1321–1331.

Hochhaus A, Reiter A, Saußele S, for the German CML Study Group and the U. K.MRC CML Study Group: Molecular heterogeneity in complete cytogenetic respon-ders after interferon-α therapy for chronic myeloid leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 95 (2000) 62–66.

James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144–1148.

Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic respon-ses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645–652.

Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus Imatinib in Newly Dia-gnosed Chronic-Phase Chronic Myeloid Leukemia. N Engl J Med 362 (2010) 2260–2270.

Landolfi R, Marchioli R, Kutti J et al. European Collaboration on Low-Dose Aspi-rin in Polycythemia Vera Investigators. Effi cacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350 (2004) 114–124.

Klampfl T, Gisslinger H, Harutyunyan AS et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 369 (2013) 2379–2390.

Mahon FX, Réa D, Guilhot J et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet On-col 11 (2010) 1029–1035.

Maxson JE, Gotlib J, Pollyea DA et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 368 (2013) 1781–1790.

Metzgeroth G, Walz C, Erben P et al. Safety and effi cacy of imatinib in chronic eo-sinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Ha-ematol 143 (2008) 707–715.

Nangalia J, Massie CE, Baxter EJ, Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 369 (2013) 2391–2405.

O‘Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994–1004.



Ottmann OG, Druker BJ, Sawyers CL et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leu-kemias. Blood 100 (2002) 1965–1971.

Pardanani A. Systemic mastocytosis in adults: 2011 update on diagnosis, risk strati-fi cation, and management. Am J Hematol 86 (2011) 362–371.

Piazza R, Valletta S, Winkelmann N et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 45 (2013) 18–24.

Preudhomme C, Guilhot J, Nicolini FE et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363 (2010) 2511–2521.

Reiter A, Invernizzi R, Cross NC, Cazzola M. Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica 94 (2009) 1634–1638.

Reiter A, Walz C, Cross NC. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Curr Drug Targets. 8 (2007) 205–216.

Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus Imatinib for Newly Diag-nosed Chronic Myeloid Leukemia. N Engl J Med362 (2010) 2251–2259.

Saussele S, Lauseker M, Gratwohl A et al. Allogeneic hematopoietic stem cell trans-plantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115 (2010) 1880–1885.

Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cyto-genetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 (2002) 3530–3539.

Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in „good-risk“ chronic granulocytic leukemia. Blood 63 (1984) 789–799.

Soverini S, Hochhaus A, Nicolini FE et al. BCR-ABL kinase domain mutation ana-lysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118 (2011) 1208–1215.

Talpaz M, Kantarjian H, Kurzrock R et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 114 (1991) 532–538.

Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 (2002) 1928–1937.

The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330 (1994) 820–825.

Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofi brosis. Curr Hematol Malig Rep 4 (2009) 33–40.

Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classifi cation of myeloid neoplasms and acute leukemia: rati-onale and important changes. Blood 114 (2009) 937–951.

Verstovsek S, Mesa RA, Gotlib J et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofi brosis. N Engl J Med. 366 (2012) 799–807.

e1711 Hodgkin-Lymphom


11 Hodgkin-LymphomBarrington SF, Mikhaeel NG, Kostakoglu L et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) Epub ahead of print.

Cheson BD, Pfi stner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579–586.

Eich HT, Diehl V, Gorgen H et al. Intensifi ed chemotherapy and dose-reduced in-volved-fi eld radiotherapy in patients with early unfavorable Hodgkin‘s lymphoma: fi nal analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28 (2010) 4199–4206.

Ekstrand BC, Lucas JB, Horwitz SM et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101 (2003) 4285–4289.

Engert A, Diehl V, Franklin J et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin‘s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27 (2009) 4548–4554.

Engert A, Haverkamp H, Kobe C et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin‘s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379 (9828) (2012) 1791–1799.

Engert A, Plutschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin‘s lymphoma. N Engl J Med 363 (2010) 640–652.

Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin‘s disease. Inter-national Prognostic Factors Project on Advanced Hodgkin‘s Disease. N Engl J Med 339 (1998) 1506–1514.

Josting A, Rudolph C, Mapara M et al. Cologne high-dose sequential chemothera-py in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 16 (2005) 116–123.

Kobe C, Kuhnert G, Kahraman D et al. Assessment of tumor size reduction im-proves outcome prediction of positron emission tomography/computed tomogra-phy after chemotherapy in advanced-stage Hodgkin lymphoma. J Clin Oncol 32 (17) (2014) 1776–1781

Küppers R. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hema-tol Educ Program 2009 (2009) 491–496.

Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009 (2009) 497–506.

Raemaekers JM, André MP, Federico M et al. Omitting radiotherapy in early posi-tron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32 (12) (2014) 1188–1194.

Swerdlow ST, Campo E, Harris NL et al. WHO Classifi cation of Tumours of Ha-ematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer 2008.



von Tresckow B, Plutschow A, Fuchs M et al. Dose-intensifi cation in early unfavo-rable Hodgkin‘s lymphoma: fi nal analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30 (2012) 907–913.

Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentu-ximab vedotin for patients with relapsed or refractory Hodgkin‘s lymphoma. J Clin Oncol 30 (18) (2012) 2183–2189.

12 Indolente (niedrig maligne) Non-Hodgkin-Lymphome

Aivado M, Schulte K, Henze L et al. Bendamustin in the treatment of chronic lym-phocytic leukemia: results and future perspectives. Semin Oncol 29 (Suppl 13) (2002) 19–22.

Barrington SF, Mikhaeel NG, Kostakoglu L et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) epub ahead of print.

Bergmann M, Goebeler M, Herold M et al. Effi cacy of bendamustin in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Acta Haematol 90 (2005) 1357–1364.

Binet J L, Auquier A, Dighiero G et al. A new prognostic classifi cation of chronic lymphocytic leukaemia derived from a multivariate survival analysis. Cancer 48 (1981) 198–204.

Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369 (2013) 32–42.

Byrd JC, Peterson BL, Morrison V et al. Randomized phase 2 study of fl udarabine with concurrent versus sequential treatment with rituximab in symptomatic, un trea-ted patients with B-cell lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101 (2003) 6–14.

Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin‘s Disease Staging Classifi cation. Cancer Res 31 (1971) 1860–1861.

Catovsky D, Richards S, Matutes E et al. Assessment of fl udarabine plus cyclophos-phamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370 (2007) 230–239.

Cheson B D, Bennet JM, Grever M et al. National Cancer Institute-sponsored wor-king group guidelines for chronic lymphocytic leukaemia: revised guidelines for di-agnosis and treatment. Blood 87 (1996) 4,990–4,997.

Damle R, Wasil T, Allen S et al. Updated data on V gene mutation status and CD38 expression in B-CLL. Blood 95 (2000) 2,456–2,457.

Dighiero G. Randomized trials: What do they teach us about chronic lymphocytic leukemia treatment? In: Cheson BD (ed.), Chronic lymphocytic leukemias. 2nd ed. Marcel Dekker, New York-Basel 2001. pp 161–174.

e1912 Indolente (niedrig maligne) Non-Hodgkin-Lymphome


Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophos-phamide. J Clin Oncol 25 (2007) 3,344–3,349.

Döhner H, Stilgenbauer S, Bener A et al. Genomic aberrations and survival in chro-nic lymphocytic leukemia. N Engl J Med 343 (2000) 1,910–1,916.

Dreger P, Corradini P, Kimby E et al. Indications for allogeneic stem cell transplan-tation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leuke-mia 21 (2007) 12–17.

Dreger P, von Neuhoff N, Kuse R et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Brit J Cancer 77 (1998) 2291–2297.

Duarte RF, Canals C, Onida F et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28 (2010) 4,492–4,499.

Dupuis J, Berriolo-Riedinger A, Julian A et al. Impact of [18F] fl uorodeoxyglucose positron emission tomography response evaluation in patients with high–tumor burden follicular lymphoma treated with immunochemotherapy: A prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol 30 35 (2012) 4317–4322.

Eichhorst B, Busch R, Stilgenbauer S et al. First-line therapy with fl udarabine com-pared with chlorambucil does not result in a major benefi t for elderly patients with advanced chronic lymphocytic leukemia. Blood 114 (2009) 3,382–3,391.

Eichhorst B, Fink AM, Busch R et al. Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Ritu-ximab (BR) in previously untreated and physically fi t patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international randomized study of the German CLL Study Group. Blood (ASH Annual Meeting Abstracts #526) 2013.

Federico M, Bellei M, Marcheselli L et al. Follicular Lymphoma International Pro-gnostic Index 2: A new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. J Clin Oncol 27 (2009) 4555–4562.

Fischer K, Cramer P, Busch R et al. Bendamustine combined with rituximab (BR) for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30 (2012) 3,209–3,216.

Flinn IW, van der Jagt R, Kahl BS et al. Randomized trial of bendamustine-ritu-ximab or R-CHOP/R-CVP in fi rst-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123 (2014): 2944–2952.

Forstpointner R, Unterhalt M, Dreyling M et al. Maintenance therapy with ritu-ximab leads to a signifi cant prolongation of response duration after salvage therapy with a combination of rituximab, fl udarabine, cyclophosphamide, and mitoxantro-ne (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108 (2006) 4003–4008.



Friedberg JW, Byrtek M, Link BK et al. Eff ectiveness of fi rst-line management stra-tegies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 30 (2012) 3,368–3,375.

Geisler CH, Kolstad A, Laurell A et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma follo-wed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 158 (2012) 355–362.

Ghielmini M, Schmitz SF, Cogliatti SB et al. Prolonged treatment with rituximab in patients with follicular lymphoma signifi cantly increases event-free survival and re-sponse duration compared with the standard weekly × 4 schedule. Blood 103 (2004) 4,416–4,423.

Goede V, Fischer K, Busch R et al. Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (clb) versus rituximab plus clb in patients with chronic lymphocytic leukemia (cll) and co-existing medical conditions comorbidities: fi nal stage 2 results of the CLL11 trial. Blood (ASH Annual Meeting Abstracts #6) 2013.

Gopal AK, Kahl BS, de Vos S et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 370 (2014) 1008–1018.

Gribben JG. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant 15 (suppl1) (2009) 53–58.

Hallek M, Cheson B, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report of the International Workshop on Chro-nic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 111 (2008) 5,446–5,556.

Hallek M, Fingerle-Rowson G, Fink AM et al. Immunochemotherapy with fl udara-bine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fl udarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leu-kemia (CLL). Blood 112 (2008) 125 (abstract 325).

Hallek M, Wanders L, Ostwald M et al. Serum β2-microglobulin and serum thymi-dine kinase are independent predictors of progression-free survival in chronic lym-phocytic leukemia and immunocytoma. Leukemia Lymphoma 22 (1996) 439–447.

Hamblin T, Orchard J, Gardiner A, Oscier D, Davis Z, Stevenson F. Immunoglo-bulin V genes and CD38 expression on CLL. Blood 95 (2000) 2,455–2,456.

Hermine O, Hoster E, Walewski J et al. Alternating courses of 3× CHOP and 3× DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: fi nal analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). ASH (2012) #151.

Herold M, Haas A, Srock S et al. Rituximab added to fi rst-line mitoxantrone, chlor ambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25 (15) (2007) 1986–1992.

e2112 Indolente (niedrig maligne) Non-Hodgkin-Lymphome


Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator‘s choice therapy for the treatment of relapsed or refrac-tory mantle cell lymphoma. J Clin Oncol 27 (2009) 3,822–3,829.

Hillmen P, Skornicki AB, Robak T et al. Alemtuzumab compared with chlorambu-cil as fi rst-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25 (2007) 5,626–5,623.

Horn H, Schmelter C, Leich E et al. Follicular lymphoma grade 3B is a distinct neo-plasm according to cytogenetic and immunohistochemical profi les. Haematologica 96 (2011) 1.327–1.334.

Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111 (2008) 558–565.

Keating M, Coutré S, Rai K et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clinical Lymphoma 4 (2004) 220–227.

Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fl udarabine: result of a large international study. Blood 99 (2002) 3,554–3,561.

Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic trans-plantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98 (2001) 3,595–3,599.

Kluin-Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367 (2012) 520–531.

Knauf WU, Langenmayer I, Ehlers B et al. Serum levels of soluble CD23, but not of soluble CD25 are predictive for disease progression in early stage B-cell chronic lymphocytic leukemia. Leukemia Lymphoma 27 (1997) 523–532.

Knauf WU, Lissichkov T, Aldaoud A et al. Bendamustine compared with chloram-bucil in previously untreated patients with chronic lymphocytic leukaemia: upda-ted results of a randomized phase III trial. Brit J Haematol 159 (2012) 67–77

Knauf WU, Lissichkov T, Aldaoud A et al. Phase III randomized study with benda-mustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27 (2009) 4,378–4,384.

Link BK, Maurer MJ, Nowakowski GS et al. Rates and outcomes of follicular lym-phoma transformation in the immunochemotherapy era: a report from the Univer-sity of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31 (2013) 3,272–3,278.

Martin P, Chadburn A, Christos P et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27 (2009) 1,209–1,213.

Meyer AH, Stroux A, Lerch K et al. Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lympho-ma. Ann Oncol 25 (1) (2014) 210–215.

Morel P, Duhamel A, Gobbi P et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113 (2009) 4,163–4,170.

Morschhauser F, Radford J, Van Hoof A et al. 90Yttrium-ibritumomab tiuxetan consolidation of fi rst remission in advanced-stage follicular non-Hodgkin lympho-ma: updated results after a median follow-up of 7.3 years from the International,



Randomized, Phase III First-Line Indolent Trial. J Clin Oncol 31 (2013) 1,977–1,983.

Musshoff K, Schmidt-Vollmer H. Proceedings: Prognosis of non-Hodgkin‘s lym-phomas with special emphasis on the staging classifi cation. Z Krebsforsch Klin On-kol Cancer Res Clin Oncol 83 (1975) 323–341.

Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambu-cil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1,750–1,757.

Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternak BS. Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975) 219–234.

Rohatiner AZ, Nadler L, Davies AJ et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or sub-sequent remission: long-term follow-up. J Clin Oncol 25 (2007) 2,554–2,559.

Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab ver-sus CHOP plus rituximab as fi rst-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-infe-riority trial. Lancet 381 (2013) 1,203–1,210.

Salles G, Seymour JF, Off ner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus che-motherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377 (2011) 42–51.

Scholz CW, Pinto A, Linkesch W et al. 90yttrium-ibritumomab-tiuxetan as fi rst-line treatment for follicular lymphoma: 30 months of follow-up data from an inter-national multicenter phase II clinical trial. J Clin Oncol 31 (2012) 308–313.

Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prog-nostic index. Blood 104 (2004) 1,258–1,265.

Treon SP, Xu L, Yang G et al. MYD88 L265P somatic mutation in Waldenstrom‘s macroglobulinemia. N Engl J Med 367 (2012) 826–833.

Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or re-fractory mantle-cell lymphoma. N Engl J Med 369 (2013) 507–516.

Wilder RB, Tucker SL, Ha CS et al. Dose-response analysis for radiotherapy deli-vered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Ra-diat Oncol Biol Phys 49 (2001) 17–22.

Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan ra-dioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin‘s lymphoma. J Clin Oncol 20 (2002) 3,262–3,269.

Witzig TE, Reeder CB, LaPlant BR et al. A phase II trial of the oral mTOR inhibi-tor everolimus in relapsed aggressive lymphoma. Leukemia 25 (2011) 341–347.

Zucca E, Conconi A, Laszlo D et al. Addition of rituximab to chlorambucil produ-ces superior event-free survival in the treatment of patients with extranodal margi-nal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 31 (2013) 565–572.

e2313 Aggressive (hoch maligne) Non-Hodgkin-Lymphome


13 Aggressive (hoch maligne) Non-Hodgkin-Lymphome

Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diff use large B-cell lym-phoma identifi ed by gene expression profi ling. Nature 403 (2000) 503–511.

Barrington SF, Mikhaeel NG, Kostakoglu L et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) epub ahead of print.

Blinder V, Fisher SG. The role of environmental factors in the etiology of lympho-ma. Cancer Invest 26 (2008) 306–316.

Boehme V, Schmitz N, Zeynalova S et al. CNS events in elderly patients with ag-gressive lymphoma treated with modern chemotherapy (CHOP-14) with or with-out rituximab: an analysis of patients treated in the RICOVER-60 trial of the Ger-man High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113 (2009) 3896–3902.

Campbell BA, Connors JM, Gascoyne RD et al. Limited-stage diff use large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiothe-rapy: involved-fi eld versus involved-node radiotherapy. Cancer 118 (2012) 4156–4165.

Cheson BD, Pfi stner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579–586.

Coiffi er B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the fi rst randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d‘Etudes des Lymphomes de l‘Adulte. Blood 116 (2010) 2040–2045.

Cunningham D, Hawkes EA, Jack A et al. Rituximab plus cyclophosphamide, do-xorubicin, vincristine, and prednisolone in patients with newly diagnosed diff use large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensifi cation with 14-day versus 21-day cycles. Lancet 381 (2013) 1817–1826.

Dunleavy K, Pittaluga S, Maeda LS et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368 (2013) 1408–1416.

Dunleavy K, Pittaluga S, Shovlin M et al. Low-intensity therapy in adults with Burkitt‘s lymphoma. N Engl J Med 369 (2013) 1915–1925.

Faris JE, LaCasce AS. Primary mediastinal large B-cell lymphoma. Clin Adv Hema-tol Oncol 7 (2009) 125–133.

Gisselbrecht C, Glass B, Mounier N et al. Salvage regimens with autologous trans-plantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28 (2010) 4184–4190.

Haioun C, Itti E, Rahmouni A et al. [18F]fl uoro-2-deoxy-D-glucose positron emis-sion tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106 (2005) 1376–1381.

Hans CP, Weisenburger DD, Greiner TC et al. Confi rmation of the molecular clas-sifi cation of diff use large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 (2004) 275–282.



Hoelzer D, Gokbuget N, Digel W et al. Outcome of adult patients with T-lympho-blastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99 (2002) 4379–4385.

Hummel M, Bentink S, Berger H et al. A biologic defi nition of Burkitt‘s lymphoma from transcriptional and genomic profi ling. N Engl J Med 354 (2006) 2419–2430.

Johnson NA, Slack GW, Savage KJ et al. Concurrent expression of MYC and BCL2 in diff use large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30 (2012) 3452–3459.

Jost LM, Jacky E, Dommann-Scherrer C et al. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt‘s lymphomas in adult patients. Ann Oncol 6 (1995) 445–451.

Lenz G, Wright G, Dave SS et al. Stromal gene signatures in large-B-cell lympho-mas. N Engl J Med 359 (2008) 2313–2323.

Oriol A, Ribera JM, Bergua J et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodefi ciency vi-rus-infected and noninfected patients. Cancer 113 (2008) 117–125.

Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9 (2008) 105–116.

Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP che-motherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104 (2004a) 626–633.

Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP che-motherapy with or without etoposide for the treatment of elderly patients with ag-gressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104 (2004b) 634–641.

Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus ri-tuximab versus CHOP-like chemotherapy alone in young patients with good-prog-nosis diff use large-B-cell lymphoma: a randomised controlled trial by the MabThe-ra International Trial (MInT) Group. Lancet Oncol 7 (2006) 379–391.

Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantati-on as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin‘s lymphoma. N Engl J Med 333 (1995) 1540–1545.

Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with re-lapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30 (2012) 2190–2196.

Reimer P, Rudiger T, Geissinger E et al. Autologous stem-cell transplantation as fi rst-line therapy in peripheral T-cell lymphomas: results of a prospective multicen-ter study. J Clin Oncol 27 (2009) 106–113.

Schmitz N, Nickelsen M, Ziepert M et al. Conventional chemotherapy (CHO-EP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, ran-domised, phase 3 trial (DSHNHL 2002–1). Lancet Oncol 13 (2012) 1250–1259.

e2514 Plasmazellneoplasien


Schmitz N, Trumper L, Ziepert M et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116 (2010) 3418–3425.

Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with dif-fuse large B-cell lymphoma treated with R-CHOP. Blood 109 (2007) 1857–1861.

Shipp MA. Prognostic factors in aggressive non-Hodgkin‘s lymphoma: who has „high-risk“ disease? Blood 83 (1994) 1165–1173.

Song KW, Barnett MJ, Gascoyne RD et al. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol 18 (2007) 535–540.

Sweetenham JW, Liberti G, Pearce R et al. High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. J Clin Oncol 12 (1994) 1358–1365.

Sweetenham JW. Treatment of lymphoblastic lymphoma in adults. Oncology (Wil-liston Park) 23 (2009) 1015–1020.

Swerdlow ST, Campo E, Harris NL et al. WHO Classifi cation of Tumours of Ha-ematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon: 2008.

Thieblemont C, Briere J, Mounier N et al. The germinal center/activated B-cell sub-classifi cation has a prognostic impact for response to salvage therapy in relapsed/refractory diff use large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 29 (2011) 4079–4087.

Thomas DA, O‘Brien S, Cortes J et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104 (2004) 1624–1630.

Vitolo U, Chiappella A, Franceschetti S et al. Lenalidomide plus R-CHOP21 in el-derly patients with untreated diff use large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 15 (2014) 730–737.

Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology fi ndings and clinical outcomes. J Clin On-col 26 (2008) 4124–4130.

Wilson WH, Dunleavy K, Pittaluga S et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diff use large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26 (2008) 2717–2724.

14 PlasmazellneoplasienBarlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous trans-plantation over standard therapy for previously untreated multiple myeloma. Blood 89 (1997) 789–793.



Criteria for the classifi cation of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J of Haemat 121 (2003) 749–757.

Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple mye-loma treated with zoledronic acid. Ann Oncol 20 (2009) 117–120.

Dimopoulos MA, Kastritis E, Rosinol L et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22 (2008) 1485–1493.

Dispenzieri A, Kyle RA, Katzmann JA et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multip-le myeloma. Blood 111 (2008) 785–789.

Dispenzieri A. Poems syndrome: 2011 update on diagnosis, risk-stratifi cation, and management. Am J Hematol 86 (2011) 591–601.

Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treat-ment, and survival. Cancer 36 (3) (1975) 842–854.

Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467–1473.

Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide ver-sus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a rando-mised trial. Lancet 370 (2007) 209–218.

Fonseca R, Bergsagel PL, Drach J et al. International myeloma working group mo-lecular classifi cation of multiple myeloma: Spotlight review. Leukemia 23 (2009) 2210–2221.

Greipp PR, San Miguel J, Durie BG et al. International Staging System for multiple myeloma. J Clin Oncol 23 (2005) 3412–3420.

Kortüm KM, Engelhardt M, Rasche L et al. Multiple Myeloma. Internist (Berl) 54 (8) (2013) 963–977.

Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed mupltiple myeloma. Mayo Clin Proc 78 (2003) 21–33.

Kyle RA, Remstein ED, Therneau TM et al. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. N Engl J Med 356 (2007) 2582–2590.

Kyle RA, Durie BG, Rajkumar SV et al. Monoclonal gammopathy of undetermined signifi cance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24 (2010) 1121–1127.

Neben K, Jauch A, Hielscheret T al. Progression in Smoldering Myeloma Is Inde-pendently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load. J Clin Oncol 31 (2013) 4325–4332.

Palumbo A, Hajek R, Delforge M et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366 (2012) 1759–1769.

Rajkumar SV. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematology Am Soc Hematol Educ Program 2012 (2012) 354–361.

e2715 Malignome des Respirationstrakts


San Miguel JF, Schlag R, Khuageva NK et al. Persistent Overall Survival Benefi t and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Pred-nisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multi-ple Myeloma. JCO 31 (2013) 448–455.

Snowden JA, Ahmedzai SH, Ashcroft J et al. Guidelines for supportive care in mul-tiple myeloma 2011. Br J Haematol 154 (2011) 76–103.

Sonneveld P, Goldschmidt H, Rosinol L et al. Bortezomib-based versus nonborte-zomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31 (2013) 3279–3287.

Terpos E, Morgan G, Dimopoulos MA et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma - related bone di-sease. J Clin Oncol 31 (2013) 2347–2357.

Zingone A, Kuehl WM. Pathogenesis of monoclonal gammopathy of undetermined signifi cance and progression to multiple myeloma. Semin Hematol 48 (2011) 4–12.

15 Malignome des RespirationstraktsAlbain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 99 (1991) 1425–1432.

Anonymous. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311 (1995) 899–909.

Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemothe-rapy in fi rst-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99 (11) (2007) 847–857.

Arriagada R, Le Chevalier T, Borie F et al. Prophylactic cranial irradiation for pati-ents with small-cell lung cancer in complete remission. J Natl Cancer Inst 87 (1995) 183–190.

Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for pati-ents with small-cell lung cancer in complete remission. N Engl J Med 431 (1999) 524–526.

Berruti A, Borasio P, Gerbino A et al. Primary chemotherapy with adriamycin, cis-platin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 81 (1999) 841–845.

Barlesi F, Scherpereel A, Rittmeyer A et al. Randomized phase III trial of mainte-nance bevacizumab with or without pemetrexed after fi rst-line induction with beva-cizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31 (2013) 3004–3011.

Betticher DC. Docetaxel in neoadjuvant therapy of early-stage non-small cell carci-noma. Onkologie 7 (Suppl) (2003) 33–36.

Bonomi P, Kim K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of pacli-



taxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18 (2000) 623–631.

Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17 (1999) 25–30.

Cardenal F, Lopez-Cabrerizo MP, Anton A et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advan-ced or metastatic non-small-cell lung cancer. J Clin Oncol 17 (1999) 12–18.

Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best sup-portive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374 (2009) 1432–1440.

Curran WJ Jr. Evolving chemoradiation treatment strategies for locally advanced non-small-cell lung cancer. Oncology 17 (2003) 7–14.

Douillard J-Y, Rosell R, Delena M et al. ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I–III) non-small cell lung cancer (NSCLC) patients: Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. Proc. ASCO (2005) Abstract #7013.

Eberhardt W, Stamatis G, Stuschke M et al. Prognostically orientated multimodali-ty treatment including surgery for selected patients of small-cell lung cancer stages IB to IIIB: long-term results of a phase II trial. Br J Cancer 81 (1999) 1206–1212.

Eberhardt WE, Albain KS, Pass H et al. Induction treatment before surgery for non-small cell lung cancer. Lung Cancer 42 (2003) S9–14.

Eckhardt JR, von Pawel J, Pujol J-L et al. Phase III study of oral compared with intravenous topotecan as second line therapy in small-cell lung cancer. J Clin Oncol 25 (2007) 2086–2092.

Fukuoka M, Furuse K, Saijo N et al. Randomized trial of cyclophosphamide, do-xorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83 (1991) 855–861.

Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefi tinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 trial). J Clin Oncol 21 (2003) 2237–2246.

Garassino MC, Martelli O, Broggini M et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 10 (2013) 981–988.

Gatzemeier U, Hossfeld DK, Neuhauss R et al. Combination chemotherapy with carboplatin, etoposide, and vincristine as fi rst-line treatment in small-cell lung can-cer. J Clin Oncol 10 (1992) 818–823.

Georgoulias V, Papadakis E, Alexopoulos A et al. Greek Oncology Cooperative Group (GOCG) for Lung Cancer. Platinum-based and non-platinum-based chemo-therapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357 (2001) 1478–1484.

Giaccone G, Herbst RS, Manegold C et al. Gefi tinib in combination with gemcita-bine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – IN-TACT 1. J Clin Oncol 22 (2004) 777–784.



Goldstraw P, Crowley J, Chanski H et al. The IASLC Lung Cancer staging project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Se-venth) Edition of the TNM Classifi cation of Malignant Tumours. J Thorac Oncol 2 (2007) 706–714.

Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as fi rst-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 6 (Suppl 1) (2001) 4–7.

Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrex-ed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589–1597.

Hanna N, Bunn PA Jr, Langer C et al. Randomized phase III trial comparing irino-tecan/cisplatin with etoposide/cisplatin in patients with previously untreated exten-sive-stage disease small-cell lung cancer. J Clin Oncol 24 (2006) 2038–2043.

Herbst RS, Giaccone G, Schiller JH et al. Gefi tinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 22 (2004) 785–794.

Hughes A, Calvert P, Azzabi A et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20 (2002) 3533–3544.

Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accele-rated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 15 (1997) 893–900.

Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 343 (2000) 1217–1222.

Kim TY, Yang SH, Lee SH et al. A phase III randomized trial of combined chemo-radiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol 25 (2002) 238–243.

Komaki R, Scott CB, Sause WT et al. Induction cisplatin/vinblastine and irradiati-on vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88–08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 39 (1997) 537–544.

Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III ran-domized trial. J Clin Oncol 20 (2002) 3578–3585.

Lassen U, Osterlind K, Hansen M et al. Long-term survival in small-cell lung can-cer: posttreatment characteristics in patients surviving 5 to 18+ years – an analysis of 1714 consecutive patients. J Clin Oncol 13 (1995) 1215–1220.

Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360–367.

Le Chevalier T, Dunant A, Arriagada R et al. Long term results of the IALT evalu-ating cisplatin-based chemotherapy in resected non-small cell lung cancer. J Clin Oncol 26 Suppl. (2008) 7507.



Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current con-cepts. Hum Pathol 9 (1978) 495–515.

Loehrer PJ, Kim K, Chen M et al. Phase-II-trial of cisplatin (P), doxorubicin (A), cyclophosphamid (C) plus radiotherapy in limited stage unresectable thymoma. Proc Am Soc Clin Oncol 14 (1994) Abstract #1375.

Marino M, Müller-Hermelink HK. Thymoma and thymic carcinoma. Relation of thymoma epithelial cells to the cortical and medullary diff erentiation of thymus. Virchows Arch A Pathol Anat Histopathol 407 (1985) 119–149.

Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 48 (1981) 2485–2492.

Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS Journal 277 (2010) 301–308.

Moertel CG, Kvols LK, O‘Connell MJ, Rubin J. Treatment of neuroendocrine car-cinomas with combined etoposide and cisplatin. Evidence of major therapeutic ac-tivity in the anaplastic variants of these neoplasms. Cancer 68 (1991) 227–232.

Mok T, Wu Y-L, Thongprasert S et al. Gefi tinib or Carboplatin-Paclitaxel in pul-monary adenocarcinoma. N Engl J Med 361 (2009) 947–957.

Natale RB, Lara PN, Chansky K et al. S0124: A randomized phase III trial compa-ring irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients with previ-ously untreated extensive stage small-cell lung cancer. J Clin Oncol 26 Suppl. (2008) 7512 abstract.

Niederle N, Krischke W, Schulz U et al. Short-term induction and cyclic mainte-nance therapy in inoperable small cell bronchial cancer. Klin Wochenschr 60 (1982) 829–838.

O‘Brien MER, Ciuleanu T-E, Tsekov H et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 (2006) 5441–5447.

Ogawa K, Toita T, Uno T et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 94 (2002) 3115–3119.

Osterlind K, Hansen HH, Hansen M et al. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol 4 (1986) 1307–1313.

Paesmans M, Sculier JP, Lecomte J et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 89 (2000) 523–533.

Paz-Ares LG, de Marinis F, Dediu M et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexedversus placebo immediate-ly after induction treatment with pemetrexed plus cisplatin for advanced nonsqua-mous non-small-cell lung cancer. J Clin Oncol 31 (2013) 2895–2902.

Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 26 (2008) 3552–3559.

Quoix E, Zalcman G, Oster JP et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378 (2011) 1079–1088.



Reck M, von Pawel J, Macha HN et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in pati-ents with small-cell lung cancer. J Natl Cancer Inst 95 (2003) 1118–1127.

Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as fi rst-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21 (2010) 1804–1809.

Rosai J. Hisological Typing of Tumours of the thymus, 2nd edn. Springer, Berlin 1999.

Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preope-rative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330 (1994) 153–158.

Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361 (2009) 958–967.

Rosell R, Carcereny E, Gervais R. Erlotinib versus standard chemotherapy as fi rst-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13 (2012) 239–246.

Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86 (1994) 673–680.

Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Car-diovasc Surg 102 (1991) 1–9.

Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevaci-zumab for non-small cell lung cancer. N Engl J Med 355 (2007) 2542–2550.

Sause W, Kolesar P, Taylor S IV et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358–364.

Scagliotti GV, Fossati R, Torri V et al. Randomized study of adjuvant chemothera-py for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 95 (2003) 1453–1461.

Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer. J Clin Oncol 26 (2008) 3543–3551.

Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regi-mens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92–98.

Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advan-ced ALK-positive lung cancer. N Engl J Med 368 (2013) 2385–2394.

Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 15 (1988) 278–299.

Sim S, Rosenzweig KE, Schindelheim R et al. Induction chemotherapy plus three-dimensional conformal radiation therapy in the defi nitive treatment of locally ad-vanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 660–665.



Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095–2103.

Shepherd FA, Pereira J, Ciuleanu TE et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) fol-lowing failure of 1st line or 2nd line chemotherapy. N Engl J Med 353 (2005) 123–132.

Sherman DM, Neptune W, Weichselbaum R et al. An aggressive approach to mar-ginally resectable lung cancer. Cancer 4 (1978) 2040–2045.

Shields TW. Preoperative radiation therapy in the treatment of bronchial carcino-ma. Cancer 30 (1972) 1388–1394.

Skarlos DV, Samantas E, Kosmidis P et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 5 (1994) 601–607.

Slotman B, Faivre-Finn C, Kramer G et al. Prophylactic cranial irradiation in exten-sive-small cell lung cancer. N Engl J Med 357 (2007) 664–672.

Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65 (1992) 956–960.

Steele JP, Shamash J, Evans MT et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18 (2000) 3912–3917.

Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodali-ty therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117 (1999) 54–63.

Sun JM, Ahn YC, Choi EK et al. Phase III trial of concurrent thoracic radiotherapy with either fi rst- or third-cycle chemotherapy for limited disease small cell lung can-cer. Ann Oncol 24 (2013) 2088–2092.

Sundstrom S, Bremnes RM, Kaasa S et al. Norwegian Lung Cancer Study Group: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol 20 (2002) 4665–4672.

Tai P, Tonita J, Yu E, Skarsgard D. Twenty-year follow-up study of long-term survival of limited-stage small-cell lung cancer and overview of prognostic and treatment factors. Int J Radiat Oncol Biol Phys 56 (2003) 626–633.

Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363 (2010) 733–742.

Treat J, Belani CP, Edelmann MJ et al. A randomized phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel carboplatin in ad-vanced stage (Stage IIIB, IV) non small cell lung cancer: Update of the Alpha Onco-logy trial. Proc ASCO (2005) Abstract #7025.

Tsuchiya R, Koga K, Matsuno Y et al. Thymic carcinoma: proposal for pathologi-cal TNM and staging. Pathol Int 44 (1994) 505–512.

Turrisi AT 3rd, Kim K, Blum R et al. Twice-daily compared with once-daily thora-cic radiotherapy in limited small-cell lung cancer treated concurrently with cispla-tin and etoposide. N Engl J Med 340 (1999) 265–271.

e3316 Malignome des Kopf- und Halsbereichs


Van Der Gaast A, Verwey J, Prins E, Splinter TA. Chemotherapy as treatment of choice in extrapulmonary undiff erentiated small cell carcinomas. Cancer 65 (1990) 422–424.

Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636–2644.

von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (1999) 658–667.

Waller D, Peake MD, Stephens RJ et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26 (2004) 173–182.

Warram J. Preoperative irradiation of cancer of the lung: fi nal report of a therapeu-tic trial. A collaborative study. Cancer 36 (1975) 914–925.

Winton TL, Livingston R, Johnson D et al. A prospective randomized trial of adju-vant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer (NSCLC) Intergroup JBR.10. Proc. ASCO (2004) Abs-tract #7018.

Winton TL, Livingston R, Johnson D et al. Vinorelbine plus cisplatin versus obser-vation in resected non-small cell lung cancer. N Engl J Med 352 (2005) 2589–2597.

Yamakawa Y, Masaoka A, Hashimoto T et al. A tentative tumor-node-metastasis classifi cation of thymoma. Cancer 68 (1991) 1984–1987.

Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as fi rst-line treat-ment for patients with advanced EGFR mutation-positive non-small-cell lung can-cer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12 (2011) 735–742.

16 Malignome des Kopf- und HalsbereichsBillan S, Kaidar-Person O, Atrash F et al. Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fl uorouracil for advanced head and neck cancer. IMAJ 15 (2013) 231–235.

Blanchard P, Baujat B, Holostenco V et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumor site. Radiother Oncol 100 (2011) 33–40.

Blanchard P, Bourhis J, Lacas B et al. Taxane-Cisplatin-Fluorouracil as induction chemotherapy in liocally advanced head and neck cancers: an individual paitent data metaanalysis of the meta-analyis of chemotherape in head and neck bacer gru-op. J Clin Oncol 31 (2013) 2854–2860.

Bonner JA, Harari PM, Giral J et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. New Engl J Med 354 (2006) 567–578.

Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregio-nally advanced head and neck cancer: 5-year survival data from a phase 3 rando-



mised trial, and relation between cetuximab-induced rash and survival. Lancet On-col 11 (2010) 21–28.

Brockmeier SJ, Ihrler S, Grosu A et al. Malignome des Nasopharynx. In: Mast G, Hrsg. Manual Kopf-Hals-Malignome. 4. Aufl . Zuckschwerdt Verlag München (2009) 234–242.

Burtness B, Goldwasser MA, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group (ECOG) study. J Clin Oncol 23 (2005) 8646–8654.

Clavel M, Vermorken JB, Cognetti et al. Randomized comparison of cisplatin, me-thotrexate, bleomycin, and vincristine versus cisplatin and 5-fl uororuracil versus cisplatin in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 5 (1994) 521–526.

Cooper JS, Zhang Q, Pajak TF et al. Long-term follow-up of the RTOG 9501/In-tergroup phase III trial: postoperative concurrent radiation therapy and chemothe-rapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84 (2012) 1198–1205.

Cornelius CP, Wollenberg B. Maligne Tumoren der inneren Nase und der Nasen-nebenhöhlen. In: Mast G, Hrsg. Manual Kopf-Hals-Malignome. 4. Aufl . Zuck-schwerdt Verlag München (2009) 221–233.

Cripps C, Winquist E, Devries MC et al. Epidermal growth factor receptor targeted therapy in stage III and IV head and neck cancer. Current Oncology 17 (2010) 37–48.

Dayyani F, Etzel CJ, Liu M et al. Meta-analysis of the impact of human papilloma virus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head & Neck Oncology 2 (2010) 15–25.

Debaere D, Vander Porten V, Nuyts S et al. Cyclophosphamide, doxorubicin and cisplatin in advanced salivary gland cancer. B-ENT 7 (2011) 1–6.

Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fl uorouracil and carboplatin plus fl uorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group stu-dy. J Clin Oncol 10 (1992) 1245–1251.

Forastiere AA, Zhang Q, Weber RS et al. Long-term results of RTOG 91–11: A comparison of three nonsurgical treatment strategies to preserve the larynx in pati-ents with locally advanced larynx cancer. J Clin Oncol 31 (2012) 845–852.

Haddad R, O‘Neill A, Rabinowits G et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIM): a randomised phase 3 trial. Lancet Oncol 14 (2013) 257–264.

Harrison LB, Sessions RB, Hong WK. Head and Neck Cancer. 2 edn. Lippincott Williams & Wilkins, Philadelphia (2004).

Hölzel D, Klamert A, Schmidt M. Krebs: Häufi gkeiten, Befunde und Behandlungs-ergebnisse. W. Zuckschwerdt Verlag München (1996).

Ihrler S, Reuschel W, Cornelius CP et al. Malignome der Kopfspeicheldrüsen. In: Mast G, Hrsg. Manual Kopf-Hals-Malignome. 4. Aufl . Zuckschwerdt Verlag Mün-chen (2009) 284–292.

e3516 Malignome des Kopf- und Halsbereichs


Jacobs C, Lyman G, Velez-Garcis E et al. A phase III randomized study comparing cisplatin and fl uorouracil as single agents and in combination for advanced squa-mous cell carcinoma of the head and neck. J Clin Oncol 10 (1992) 257–263.

Jin Y, Cai XY, Shi YX et al. Comparison of fi ve cisplatin-based regimens frequent-ly used as the fi rst-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol 138 (2012) 1717–1725.

Kish JA, Ensley JF, Jacobs J et al. Randomized trial of cisplatin + 5-fl uorouracil infusion and cisplatin + 5-FU bolus for recurrent and advanced squamous cell car-cinoma of the head and neck. Cancer 56 (1985) 2740–2744.

Liang ZG, Zhu XD, Zhou ZR et al. Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of 793 pati-ents form 5 randomized controlled trials. Asian Pac J Cancer Prev 13 (2012) 5747–5752.

Licitra L, Störker S, Kerr KM et al. Predictive value of epidermal growth factor re-ceptor expression for fi rst-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYS-TAL studies. EJC 49 (2013) 1161–1168.

Ma J, Liu Y, Yang X et al. Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis. World J Surg Oncol 11 (2013) 67–73.

Matthias C, Panzer M, Röper B. Oropharynxtumoren. In: Mast G, Hrsg. Manual Kopf-Hals-Malignome. 4. Aufl . Zuckschwerdt Verlag München (2009) 256–262.

Munker R, Wollenberg B, Schalhorn A. Grundzüge der Chemotherapie bei Kopf-Hals-Tumoren. In: Wollenberg B, Zimmermann F, Hrsg. Manual Kopf-Hals-Mali-gnome. 3. Aufl . Zuckschwerdt Verlag München (2003) 41–47.

Paccagnella A, Ghi MG, Loreggian L et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5-fl uororuacil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II rando-mized trial. Ann Oncol 21 (2010) 1515–1522.

Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treat-ment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355 (2000) 949–955.

Pignon JP, le Maitre A, Maillard E et al. On behalf of MACH-NC Collaborative Group: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomized trial in 17.346 patients. Radiother Oncol 92 (2009) 4–14.

Pigorsch S, Gosau M, Panzer M et al. Tumoren der Mundhöhle und Lippen. In: Mast G, Hrsg. Manual Kopf-Hals-Malignome. 4. Aufl . Zuckschwerdt Verlag Mün-chen (2009) 234–242.

Pigorsch S, Röper B, Wypior H et al. Allgemeine Grundsätze der Strahlentherapie. In: Mast G, Hrsg: Manual Kopf-Hals-Malignome. 4. Aufl . Zuckschwerdt Verlag München (2009) 70–77.

Pointreau Y, Garaud P, Chapet S et al. Randomized trial of induction chemothera-py with cisplatin and 5-fl uorouracil with or without docetaxel for larynx preserva-tion. J Natl Cancer Inst 101 (2009) 498–506.



Posner MR, Hershok DM, Blajman CR et al. Cisplatin and fl uorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007) 1705–1715.

Reiter M, Harréus U, Matthias C et al. Epidemiologie. In: Mast G, Hrsg. Manual Kopf-Hals-Malignome. 4. Aufl . Zuckschwerdt Verlag München (2009) 9–17.

Röper B, Matthias C, Panzer M et al. Malignome des Hypopharynx und oberen Ösophagus. In: Mast G, Hrsg. Manual Kopf-Hals-Malignome. 4. Aufl . Zuck-schwerdt Verlag München (2009) 263–271.

Rowan K. Should cetuximab replace cisplatin in head and neck cancer? JNCI 102 (2010) 74–78.

Schalhorn A. Chemotherapie der fortgeschrittenen Kopf-Hals-Tumoren. Onkologe 2 (1996) 352–358.

Schlesinger-Raab A, Lang S, Steuer-Vogt MK et al. Zur Epidemiologie der Kopf-Hals-Malignome. Manual Kopf-Hals-Malignome, Tumorzentrum München und Zuckschwerdt Verlag München (2003).

Schornagel JH, Verweij J, De Mulder PMH et al. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squa-mous cell carcinoma of the head and neck. J Clin Oncol 13 (1995) 1649–1655.

Specenier PM, Vermorken JB. Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther 8 (2008) 375–391.

Sturgis EM, Wei Q, Spitz MR. Descriptive epidemiology and risk factors for head and neck cancer. Sem Oncol 31 (2004) 726–733.

Tejani M, Cohen RB, Mehra R. The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics: Targets & Therapy 4 (2010) 173–185.

Terhaard CHJ, Lubsen H, Rasch CRN et al. The role of radiotherapy in the treat-ment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 61 (2005) 101–111.

Thibaudeau E, Fortin B, Coutlée F et al. HPV Prevalence and prognostic value in a prospective cohort of 255 patients with locally advanced HNSCC: a single-centre experience. Int J Otolaryngol (2013) Article ID 437815. doi:10.1155/2013/437815.

Urba S, van Herpen CM, Sahoo TP et al. Pemeterexed in combination with cispla-tin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: fi nal results of a randomized, double-blind, placebo-controlled phase 3 study. Cancer 118 (2012) 4694–4705.

Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fl uorouracil, and doceta-xel in unresectable head and neck cancer. N Engl J Med 357 (2007) 1695–1704.

Vermorken JB, Mesia R, Rivera F et al. Platinum based chemotherapy plus cetu-ximab in head and neck cancer. N Engl J Med 359 (2008) 1116–1127.

Vogl SE, Schoenfeld DA, Kaplan BA et al. A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 56 (1985) 432–442.

Wittekind Ch, Meyer HJ, Bootz F. TNM Klassifi kation maligner Tumoren. 6. Aufl . Springer Berlin (2003).

Zhong LP, Zhang CP, Ren GX et al. Randomized phase III trial of induction che-motherapy with docetaxel, cisplatin, and fl uorouracil followed by surgery versus

e3717 Malignome des Gastrointestinaltrakts


up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 31 (2013) 744–751.

Zimmermann F, Matthias C. Malignome des Kehlkopfes. In: Mast G, Hrsg. Manu-al Kopf-Hals-Malignome. 4. Aufl . Zuckschwerdt Verlag München (2009) 272–280.

17 Malignome des Gastrointestinaltrakts

17.1 ÖsophaguskarzinomAjani JA, Ilson DH, Daugherty K et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86 (1994) 1086–1091.

Bancewicz J, Clark PI, Smith DB et al. Surgical resection with or without preopera-tive chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359 (2002) 1727–1733.

Bedenne L, Michel P, Bouche O et al. Chemoradiation followed by surgery compa-red with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25 (10) (2007) 1160–1168.

Cooper JS, Guo MD, Herskovic A et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA 281 (1999) 1623–1627.

Engel LS, Chow WH, Vaughan TL et al. Population attributable risks of esophage-al and gastric cancers. J Natl Cancer Inst 95 (2003) 1404–1413.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and morta-lity patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49 (6) (2013) 1374–403.

Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesopha-geal cancer: a systematic review and meta-analysis. Gut 53 (2004) 925–930.

GASTRIC Group, Paoletti X, Oba K et al. Benefi t of Adjuvant Chemotherapy for Resectable Gastric Cancer. JAMA 303 (17) (2010) 1729–1737.

Gebski V, Burmeister B, Smithers BM et al. Survival benefi ts from neoadjuvant che-moradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lan-cet Oncol 8 (3) (2007) 226–234.

Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gas-troesophageal refl ux disease and its complications. Ann Intern Med 143 (2005) 199–211.

Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compa-red with surgery alone for localized esophageal cancer. New Engl J Med 339 (1998) 1979–1984.

Malthaner R, Fenlon D. Preoperative chemotherapy for resectable thoracic esopha-geal cancer. Cochrane Database Syst. Rev 1 (2001) CD001556.

Möhler M, Al-Batran SE, Andus T et al. S3-Leitlinie Magenkarzinom. Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs. Z Gastroenterol 49 (2011) 461–531.



Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 310 (6) (2013) 627–636.

Ronellenfi tsch U, Schwarzbach M, Hofheinz R et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gas-troesophageal junction, and lower esophagus. Cochrane Database Syst Rev 5 (2013) CD008107.

Tramacere I, La Vecchia C, Negri E. Tobacco smoking and esophageal and gastric cardia adenocarcinoma: a meta-analysis. Epidemiology 22 (3) (2011) 344–349.

Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compa-red neoadjuvant chemoradiation and surgery to surgery alone for resectable eso-phageal cancer. Am J Surg 185 (2003) 538–543.

van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366 (22) (2012) 2074–2084.

Wijnhoven BP, van Lanschot JJ, Tilanus HW et al. Neoadjuvant chemoradiothera-py for esophageal cancer: a review of meta-analyses. World J Surg 33 (12) (2009) 2606–2614.

Ychou M, Boige V, Pignon JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29 (13) (2011) 1715–1721.

17.2 MagenkarzinomAl-Batran SE, Hartmann JT, Hofheinz R et al. Biweekly fl uorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19 (11) (2008a) 1882–1887.

Al-Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroeso-phageal adenocarcinoma with fl uorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26 (9) (2008b) 1435–1442.

Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 23 (26) (2005) 6415–6420.

Bang YJ, Van CE, Feyereislova A et al. Trastuzumab in combination with chemo-therapy versus chemotherapy alone for treatment of HER2-positive advanced gast-ric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, rando-mised controlled trial. Lancet 376 (9742) (2010) 687–697.

Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358 (1) (2008) 36–46.

Cunningham D, Allum WH, Stenning SP et al. NCRI Upper GI Cancer Clinical Studies Group: Perioperative chemotherapy versus surgery alone for resectable gas-troesophagal cancer. N Engl J Med 355 (1) (2006) 11–20.

Dank M, Zaluski J, Barone C et al. Randomized phase III study comparing irinote-can combined with 5-fl uorouracil and folinic acid to cisplatin combined with 5-fl u-orouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19 (8) (2008) 1450–1457.



Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RE-GARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (9911) (2014) 31–39.

Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol 23 (25) (2005) 6220–6232.

Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EX-PAND): a randomised, open-label phase 3 trial. Lancet Oncol 14(6) (2013) 490–499.

Lutz MP, Wilke H, Wagener DJ et al. Weekly infusional high-dose fl uorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly ci-splatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 25 (18) (2007) 2580–2585.

MacDonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesopha-geal junction. N Engl J Med 345 (10) (2001) 725–730.

Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fl uorouracil compared with cisplatin and fl uorouracil as fi rst-line the-rapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24 (31) (2006) 4991–4997.

Waddell T, Chau I, Cunningham Det al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oe-sophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet On-col 14 (6) (2013) 481–489.

Webb A, Cunningham D, Scarff e JH et al. Randomized trial comparing epirubicin, cisplatin, and fl uorouracil versus fl uorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15 (1) (1997) 261–267.

17.3 PankreaskarzinomAranda E, Manzano JL, Rivera F et al. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Annals of Oncology 23 (7) (2012) 1919–1925.

Artinyan A, Soriano PA, Prendergast C. The anatomic location of pancreatic can-cer is a prognostic factor for survival. HPB (Oxford) 10 (5) (2008) 371–376.

Belli C, Cereda S, Anand S, Reni M. Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treatment Reviews 29 (5) (2013) 518–524.

Berger AC, Winter K, Hoff man JP et al. Five year results of US intergroup/RTOG 9704 with postoperative CA 19–9 ≤90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys 84 (3) (2012) 291–297.

Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combina-tion with fl uorouracil versus gemcitabine alone in patients with advanced pancrea-



tic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20 (15) (2002) 3270–3275.

Bujanda L, Herreros-Villanueva M, Hijona E, Cosme A. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 18 (14) (2012) 1565–1572.

Burris 3rd HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefi t with gemcitabine as fi rst-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (6) (1997) 2403–2413.

Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical be-nefi t with gemcitabine as fi rst-line therapy for patients with advanced pancreas can-cer: a randomized trial. J Clin Oncol 15 (6) (1997) 2403–2413.

Chauff ert B, Mornex F, Bonnetain F, Rougier P, Mariette C. Phase III trial compa-ring intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermit-tent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Defi nitive results of the 2000–01 FFCD/SFRO study. Annals of Oncology 19 (9) (2008) 1592–1599.

Chiorean EG, Von Hoff DD, Ervin TJ et al. CA19–9 decrease at 8 weeks as a pre-dictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metas-tatic pancreatic cancer (MPC). J Clin Oncol 31 (Suppl) (2013) Abstr. 4058.

Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus Gemcitabine for Me-tastatic Pancreatic Cancer. N Engl J Med 364 (19) (2011) 1817–1825.

Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M. The role of the FOLFI-RINOX regimen for advanced pancreatic cancer. Current Oncology Reports 15 (2) (2013) 182–189.

Fukutomi A, Uesaka K, Boku N, H et al. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pan-creatic cancer. J Clin Oncol 31 (2013) (suppl. abstr 4003).

Gastrointestinal Tumor Study Group. Further evidence of eff ective adjuvant com-bined radiation and chemotherapy following curative resection. Cancer 59 (12) (1987) 2006–2010.

Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: A systemic review and meta-analysis of response and resection percentages. PLos Medicine 7 (4) (2010) e1000267.

Gonçalves A, Gilabert M, François E et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus pla-cebo in patients with advanced pancreatic cancer. Annals of Oncology 23 (11) (2012) 2799–2805.

Gunturu KS, Rossi GR, Saif MW. Immunotherapy updates in pancreatic cancer: are we there yet? Therapeutic Advances in Medical Oncology 5 (1) (2013) 81–89.

Habermehl D, Kessel K, Welzel T, Hof H et al. Neoadjuvant chemoradiation with gemcitabine for locally advanced pancreatic cancer. Radiat Oncol 7 (2012) 28.

Hammel P, Huguet F, Van Laethem JL et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic can-cer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Fi-nal results of the international phase III LAP 07 study. 2013 ASCO Annual Meeting. J Clin Oncol 31 (2013) (suppl; abstr LBA4003).



Hardacre JM, Mulcahy MF, Small W et al. Addition of algenpantucel-L immuno-therapy to standard of care (SOC) adjuvant therapy for pancreatic cancer. J Clin Oncol 30 (2012) (suppl; abstr 4049).

Haslam JB, Cavanaugh PJ, Stroup LS. Radiation therapy in the treatment of irre-sectable adenocarcinoma of the pancreas. Cancer 32 (1973) 1341–1345.

Hassan MM, Bondy ML, Wolff RA et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 102 (12) (2007) 2696–2707.

Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of rando-mized trials: evaluation of benefi t from gemcitabine-based combination chemothe-rapy applied in advanced pancreatic cancer. BMC Cancer 8 (2008) 82.

Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal carcinoma: Rationale and current evidence for new therapeutic strategies. Cancer Treat Rev 40 (2014) 118–128.

Heinemann V, Vehling-Kaiser U, Waldschmidt D et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabi-ne in advanced pancreatic cancer: fi nal results of a randomised phase 3 trial of the ‚Arbeitsgemeinschaft Internistische Onkologie‘ (AIO-PK0104). Gut 62 (5) (2013) 751–762.

Herman JM, Wild AT, Wang H et al. Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Ad-vanced Pancreatic Cancer. J Clin Oncol 31 (2013) 886–894.

Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine compa-red with gemcitabine alone in advanced pancreatic cancer: a randomized, multicen-ter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25 (16) (2007) 2212–2217.

Hidalgo M. Pancreatic cancer. N Engl J Med 362 (2010) 1605–1617.

Ho AH. FOLFIRINOX: A small step or a great leap forward. J Clin Oncol 29 (28) (2011) 3727–3729

Hosein PJ, Macintyre J, Kawamura C et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 12 (2012) 199.

Ioka T, Katayama K, Ishida N et al. Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer. J Clin Oncol 30 (Suppl. 34) (2012) abstr. 287.

Kaiser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and che-motherapy following curative resection. Archives of Surgery 120 (8) (1985) 899–903.

Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compa-red with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28 (22) (2010) 3617–3622.

Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML. Adjuvant Radiothe-rapy and 5-Fluorouracil after curative resection of cancer of the pancreas and pe-riampullary region. Annals of Surgery 230 (6) (1999) 776–782.

Larsson SC, Wolk A. Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer 106 (3) (2012) 603–607.



Leach B. Priority Review Granted for nab-paclitaxel in metastatic pancreatic can-cer. Auf: www.onclive.com/web-exclusives/Priority-Review-Granted-for-Nab-Pac-litaxel-in-Metastatic-Pancreatic-Cancer (letzter Zugriff : 18.7.2014).

Li D, Morris JS, Liu J et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 301 (24) (2009) 2553–2562.

Liao KF, Lai SW, Li CI, Chen WC. Diabetes mellitus correlated with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol 27 (4) (2012) 709–713.

Loehrer Sr PJ, Feng Y, Cardenes H et al. Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eas-tern Cooperative Oncology Group Trial. L Clin Oncol 29 (31) (2011) 4105–4112.

Lombardi L, Troiano T, Silvestris N et al. Combined modality treatments in pan-creatic cancer. Expert Opin Ther Targets 16 (Suppl. 2) (2012) S71–81.

Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxalipla-tin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 (15) (2005) 3509–3516.

Mahaseth H, Kauh JS, Brutcher E, Hawk NN, Kim S, Chen Z, El-Rayes BF. Safety and effi cacy of modifi ed FOLFIRINOX in pancreatic cancer: a retrospective experi-ence. 2012 ASCO Annual Meeting. J Clin Oncol; 30 (2012) abstr e14614.

Maitra A, Hruban HR. Pancreatic cancer. Annu Rev Pathol 3 (2008) 157–188.

Malik NK, May KS, Chandrasekhar R et al. Treatment of locally advanced unre-sectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol 3(4) (2012) 326–334.

Masamune A, Shimosegawa T. Signal transduction in pancreatic stellate cells. J Gastroenterol 44 (4) (2009) 249–260.

Mizuno N, Yamao K, Komatsu Y et al. Randomized phase II study of best availab-le fl uoropyrimidine compared with continuation of gemcitabine (Gem) monothera-py in patients with Gem-refractory pancreatic cancer. J Clin Oncol 30 (Suppl. 34) (2012) abstr. 263.

Moertel CG, Childs Jr DS, Reitemeier RJ, Colby Jr MY, Holbrook MA. Combined 5-fl uorouracil and supervoltage radiation therapy of locally unresectable gastroin-testinal cancer. Lancet 2 (1969) 865–867.

Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (15) (2007) 1960–1966.

Moore MJ, Von Hoff DD, Ervin TJ et al. Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemci-tabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC). J Clin Oncol 31 (2013) (suppl; abstr. 4059).

Mukherjee S, Hurt C, Griffi ths G et al. SCALOP: Results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LAN-PC). J Clin Oncol 30 (2012) (suppl 34; abstr LBA146).



Mulcahy N. FDA approves nab-paclitaxel for pancreatic cancer. Auf: www.med-scape.com/viewarticle/810564 (letzter Zugriff : 18.7.2014).

Nakamura M, Kayashima T, Fujiwara K, Nagayoshi Y, Kono H. Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer. Hepatogastroenterology 60 (122) (2013) 354–357.

National Comprehensive Cancer Network. NCCN Guidelines and Compendium Updated. Updates for Pancreatic Adenocarcinoma. Auf: www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=36 (letzter Zugriff : 18.7.2014).

Neesse A, Michl P, Frese KK et al. Stromal biology and therapy in pancreatic can-cer. Gut 60 (6) (2011) 861–868.

Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant Chemotherapy With Fluo-rouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. J Am Med Assoc 304 (10) (2010) 1073–1081.

Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiothe-rapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (12) (2004) 1200–1210.

O’Reilly E. Refi nement of adjuvant therapy for pancreatic cancer. JAMA 304 (10) (2010) 1124–1125.

Oettle H, Neuhaus P, Hochhaus A et al. Adjuvant therapy with gemcitabine and long-term outcomes among patients with resectable pancreatic cancer: The CON-KO-001 randomized trial. JAMA 310 (14) (2013) 1473–1481.

Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. J Am Med Assoc 297 (3) (2007) 267–277.

Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pan-creatic cancer. Annals of Oncology 16 (10) (2005) 1639–1645.

Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. European Journal of Cancer 44 (7) (2008) 946–953.

Palmer DH, Stocken DD, Hewitt H et al. A randomized phase 2 trial of neoadju-vant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gem-citabine combined with cisplatin. Annals of Surgical Oncology 14 (7) (2007) 2088–2089.

Pelzer U, Kubica K, Stieler J et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26 (15S) (2008) (suppl; abstr 4508).

Pelzer U, Schwaner I, Stieler J et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fl uorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Euro-pean Journal of Cancer 47 (11) (2011) 1676–1681.

Philip PA, Benedetti J, Corless CL et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcino-ma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28 (22) (2010) 3605–3610.



Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemothera-py before and after fl uorouracil-based chemoradiation following resection of pan-creatic adenocarcinoma: a randomized controlled trial. J Am Med Assoc 299 (9) (2008) 1019–1026.

Rocha Lima CM, Gree MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22 (18) (2004) 3776–3783.

Seuff erlein T, Porzner M, Becker T et al. [S3-guideline exocrine pancreatic cancer.] Z Gastroenterol 51 (12) (2013) 1395–1440.

Shi C, Hruban HR, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 133 (3) (2009) 365–374.

Smeenk HG, van Eijck CHJ, Hop WC et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Annals of Surgery 246 (5) (2007) 734–740.

Spano JP, Chodkiewicz C, Maurel J et al. Effi cacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371 (2008) 2101–2108.

Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and fu-ture challenges. Nat Rev Clin Oncol 7 (2010) 163–172.

Stocken DD, Büchler MW, Dervenis C et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer, Br J Cancer 92 (8) (2005) 1372–1381.

Sultana A, Smith CT, Cunningham D et al. Meta-analyses of chemotherapy for lo-cally advanced and metastatic pancreatic cancer. J Clin Oncol 25 (18) (2007) 2607–1265.

Trieu V, Hwang J, Desai N. Nanoparticle albuminbound (nab) technology may enhance antitumour activity via targeting of SPARC protein, Proceedings. New Targets and Delivery System for Cancer Diagnosis and Treatment conference, Sid-ney Kramer Cancer Center, San Diego (2007) abstr 53.

van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27 (13) 2009 2231–2237.

Verslype C, Verwvenne W, Bennouna J et al. Rash as a marker for the effi cacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study. J Clin Oncol 27 (Suppl) (2009) abstr 4532.

Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lan-cet 378 (2011) 607–620.

Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (2013) 1691–1703.

Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol 29 (34) (2011) 4548–4554.

Wolfgang CL, Herman JM, Laheru DA et al. Recent progress in pancreatic cancer. CA: A Cancer Journal for Clinicans 63 (5) (2013) 318–348.



Xiong HQ, Varadhachary GR, Blais JC et al. Phase 2 trial of oxaliplatin plus cape-citabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113 (8) (2008) 2046–2052.

17.4 Cholangiozelluläres und GallenblasenkarzinomAgrawal S, Belghiti J. Oncologic Resection for Malignant Tumors of the Liver. Ann Surg 253 (4) (2011) 656–665.

André T, Reyes-Vidal JM, Fartoux L et al. Gemcitabine and oxaliplatin in advan-ced biliary tract carcinoma: a phase II study. Br J Cancer 99 (6) (2008) 862–7.

Cardinale V, Semeraro R, Torrice A et al. Intra-hepatic and extra-hepatic cholan-giocarcinoma: New insight into epidemiology and risk factors. World J Gastroin-test Oncol 2 (11) (2010) 407–416.

Grossman EJ, Millis JM. Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature. Liver Transpl 16 (8) (2010) 930–942.

Hong K, Geschwind JF. Locoregional intra-arterial therapies for unresectable in-trahepatic cholangiocarcinoma. Semin Oncol 37 (2) (2010) 110–117.

Knox JJ, Hedley D, Oza A et al. Combining gemcitabine and capecitabine in pati-ents with advanced biliary cancer: a phase II trial. J Clin Oncol 23 (10) (2005) 2332–2338.

Liu F, Li Y, Wei Y, Li B. Preoperative Biliary Drainage Before Resection for Hilar Cholangiocarcinoma: Whether or Not? A Systematic Review. Dig Dis Sci 56 (3) (2010) 663–672.

Nathan H, Pawlik TM. Staging of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 26 (3) (2010) 269–273.

Nehls O, Oettle H, Hartmann JT et al. Capecitabine plus oxaliplatin as fi rst-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 98 (2) (2008) 309–315.

Tischendorf JJ, Geier A, Trautwein C. Current diagnosis and management of pri-mary sclerosing cholangitis. Liver Transpl 14 (6) (2008) 735–746.

Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 (14) (2010) 1273–1281.

Witzigmann H, Berr F, Ringel U et al. Surgical and palliative management and out-come in 184 patients with hilar cholangiocarcinoma: palliative photodynamic the-rapy plus stenting is comparable to r1/r2 resection. Ann Surg 244 (2) (2006) 230–239.

17.5 Hepatozelluläres KarzinomBosetti C, Levi F, Boff etta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology 48 (2008) 137–145.

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepa-tology 53 (3) (2011) 1020–1022.



Chen JD, Yang HI, Iloeje UH et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138 (2010) 1747–1754.

Cheng A, Kang Y, Chen Z et al. Effi cacy and safety of sorafenib in patients in the Asia-Pacifi c region with advanced hepatocellular carcinoma: a phase III rando-mised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009) 25–34.

Cheng B, Jia C, Liu C et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA 299 (14) (2008) 1669–1677.

Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49 (2009) 453–459.

Di Bisceglie AM, Shiff man ML, Everson GT et al. HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359 (2008) 2429–2441.

Di Bisceglie AM. Hepatitis B and Hepatocellular Carcinoma. Hepatology 49 (2009) S56–S60.

El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepa-tocellular carcinoma. Gastroenterology 134 (2008) 1752–1763.

Greten TF, Malek NP, Schmidt S et al. S3-Leitlinie Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 51 (2013) 1269–1326.

Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treat-ment of hepatocellular carcinoma. Liver Transpl 10 (2004) S115–120.

Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carci-noma. N Engl J Med 359 (2008) 378–390.

Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplanta-tion in patients with hepatocellular carcinoma beyond the Milan criteria: a retro-spective, exploratory analysis. Lancet Oncol 10 (2009) 35–43.

Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693–699.

Sherman M. Hepatocellular carcinoma: Epidemiology, surveillance, and diagnosis. Semin Liver Dis 30 (1) (2010) 3–16.

Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of beva-cizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27 (2009) 843–850.

Wang N, Guan Q, Wang K et al. TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis. Med Oncol 28 (2011) 1038–1043.

Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, Chen CJ. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infec-tion. J Clin Oncol 28 (14) (2010) 2437–2444.

Zhou Y, Zhao Y, Li B et al. Meta-analysis of radiofrequency ablation versus hepa-tic resection for small hepatocellular carcinoma. BMC Gastroenterology 10 (2010) 78.



17.7 Kolorektales Karzinomde Gramont A, Figer A, Seymour M et al. Leucovorin and fl uorouracil with or wit-hout oxaliplatin as fi rst-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938–2947.

Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fl uoroura-cil compared with fl uorouracil alone as fi rst-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041–1047.

Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepa-tic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999) 309–318.

Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fl uorouracil-leucovorin as fi rst-line treat-ment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136–147.

Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previous-ly treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013) 303–312.

Hohenberger P. Colorectal cancer – what is standard surgery? Eur J Cancer 37 (Suppl 7) (2001) S173–S187.

Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fl uo-rouracil and leucovorin in fi rst-line metastatic colorectal cancer: results of a rando-mized phase II trial. J Clin Oncol 23 (2005) 3697–3705.

Kohne CH, Van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusi-onal fl uorouracil plus folinic acid with or without irinotecan in patients with meta-static colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40.986. J Clin Oncol 23 (2005) 4856–4865.

Ross P, Norman A, Cunningham D et al. A prospective randomised trial of protrac-ted venous infusion 5-fl uorouracil with or without mitomycin C in advanced colo-rectal cancer. Ann Oncol 8 (1997) 995–1001.

Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fl uorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl. J Med 343 (2000) 905–914.

Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor recep-tor. J Clin Oncol 22 (2004) 1201–1208.

Tabernero J, Van Cutsem E, Lakomý R et al. Afl ibercept versus placebo in combi-nation with fl uorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecifi ed subgroup analyses from the VE-LOUR trial. Eur J Cancer 50 (2014) 320–331.

Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 (2005) 2696–2704.



17.8 AnalkarzinomBartelink H, Roelofsen F, Eschwege F et al. Concomitant radiotherapy and chemo-therapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15 (1997) 2040–2049.

Faivre C, Rougier P, Ducreux M et al. [5-fl uorouracile and cisplatinum combinati-on chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer 86 (1999) 861–865.

Frisch M, Glimelius B, van den Brule AJ et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337 (1997) 1350–1358.

18 Malignome des UrogenitaltraktsAdvanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemothera-py in invasive bladder cancer: update of a systematic review and a meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaborati-on. Eur Urol 49 (2005) 202–205.

Albers P, Siener R, Krege S et al. Randomized Phase III trial comparing retroperito-neal lymph node dissection with one course of bleomycin and etoposide plus cispla-tin chemotherapy in adjuvant treatment of clinical stage I nonseminomatous testi-cular germ cell tumors: AUO trial AH 01/09 by the German Testicular Cancer Stu-dy Group. J Clin Oncol 26 (2008) 2966–2972.

Amdur RJ, Parsons JT, Fitzgerald LT et al. The eff ect of overall treatment time on local control in patients with adenocarcinoma of the prostate treated with radiati-on therapy. Int J Radiat Oncol Biol Phys 19 (1990) 1377–1382.

Aparicio J, Germa JR, Garcia del Muro X et al. Risk-adapted management for pa-tients with clinical stage I seminoma: the second Spanish Germ Cell Cancer Coope-rative Group study. J Clin Oncol 23 (2005) 8717–823.

Ash D, Flynn A, Battermann J et al. ESTR0/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother. Oncol 57 (2000) 315–321.

Babjuk M, Oosterlinck R, Sylvester E et al. Guidelines on TaT1 (non-muscle inva-sive) bladder cancer. European Ass of Urology 2008.

Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinfl unine plus best sup-portive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27 (2009) 4454–4461.

Beyer J, Alber P, Altena R et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Annals of Oncol 24 (2013) 878–888.

Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemothe-rapy compared to standard-dose PEB/VIP chemotherapy in patients with advanced

e4918 Malignome des Urogenitaltrakts


germ cell tumors: a multivariate and matched pair analysis. J Clin Oncol 17 (1999) 3450–3456.

Bokemeyer C, Oechsle K, Honecker F et al. Combination chemotherapy with gem-citabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 19 (2008) 448–453.

Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally ad-vanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 337 (1997) 295–300.

Bolla M, van Poppel H, van Cangh P et al. Does postoperative radiotherapy after radical prostatectomy improve progression free survival in pT3N0 prostate cancer? J Clin Oncol 23 (2004) 282.

Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80 (2000) 1198–1220.

Cathomas R, Hartmann M, Krege S et al. Interdisciplinary evidence-based recom-mendations for the follow-up of testicular cancer patients. Onkologie 34 (2011) 59–64.

Chen MF, Chen WC, Wu CT et al. Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan. World J Urol 22 (2004) 60–66.

Czeloth K, Albers P. „Active surveillance“ des lokalisierten Prostatakarzinoms. Onkologe 13 (2007) 691–700.

de Bono JS, Logothetis CJ, Fizazi K et al. Abiraterone Acetate (AA) plus low dose prednisone (p) improves overall survival (OS) in patients (pts) with metastatic cast-ration-resistant prostate cancer (MCRPC) who have progressed after docetaxel-based chemotherapy (Chemo): results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Annals of Oncol 21 (2010) Suppl. 8.

de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitox-antrone for metastatic castration-resistant prostate cancer progressing after doceta-xel treatment: a randomised open-label trial. Lancet. 376 (2010) 1147–1154.

de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011) 1995–2005.

Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, do-xorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100 (2004) 1639–1645.

Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 356 (2007) 125–134.

Escudier B, Eisen T, Porta C et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 (suppl 7) (2012) vii65–vii71.

Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cyst-ectomy compared with cystectomy alone for locally advanced bladder cancer. New Engl J Med 349 (2003) 859–866.

Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemo-therapy for disseminated nonseminomatous germ cell tumors: prognostic factors



and role of postsurgery chemotherapy – results from an international study group. J Clin Oncol 15;19 (2001) 2647–2657.

Fossa SD, Stenning SP, Gerl A et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80 (1999) 1392–1399.

Höcht S, Weigel T, Schostak M, Hinkelbein W. Adjuvant and salvage radiotherapy (RT) after radical prostatectomy. Onkologie 25 (2003) 201–206.

Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carbopla-tin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer In-stitute trial. J Clin Oncol 25 (2007) 2218–2224.

International Germ Cell Cancer Collaborative Group (IGCCCG): The Internatio-nal Germ Cell Consensus Classifi cation: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15 (1997) 594–603.

International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based fi rst-line chemotherapy. J Clin Oncol 28 (2010) 4906–4911.

Kenfi eld SA, Stampfer MJ, Giovannucci E et al. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 29 (2011) 726–732.

Kollmannsberger C, Soulieres D, Wong R et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side eff ects. Can Urol Assoc J 1 (2 Suppl) (2007) S41–54.

Kondagunta GV, Bacik J, Bajorin D et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 23 (2005) 9290–9294.

Lehmann J, Retz M, Wiemers C et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicine, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23 (2005) 4963–4974.

Linardou H, Aravantinos G, Efstathiou E et al. Gemcitabine and carboplatin com-bination as fi rst-line treatment in elderly patients and those unfi t for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Group. Urology 64 (2004) 479–484.

Loehrer PJ sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in pati-ents with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992) 1066–1073.

Lorch A, Kollmannsberger C, Hartmann JT et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ-cell tumors: a pro-spective randomized multicenter trial of the German testicular cancer study group. J Clin Oncol. 25 (2007) 2778–2784.

Lorch A, Rick O, Wündisch T et al. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. J Urol 184 (2010) 168–173.

Lorch A, Bascoul-Mollevi C, Kramer A et al. Conventional-dose versus high-dose che-motherapy as fi rst salvage treatment in male patients with metastatic germ cell tu-mors: evidence from a large international database. J Clin Oncol 29 (2011) 2178–2184.

e5118 Malignome des Urogenitaltrakts


Motzer RJ, Mazumdar M, Bacik J et al. Survival and Prognostik stratifi cation of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17: 2530–2540.

Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon-alfa in metas-tatic renal-cell carcinoma. New Engl J Med 356 (2007) 115–124.

Motzer RJ, Escudier B, Oudard S et al. Effi cacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449–456.

Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic re-nal-cell carcinoma. N Engl J Med 369 (8) (2013a) 722–733.

Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14(6) (2013b) 552–562.

Oldenburg J, Fossa SD, Nuver J et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncol 24 (Suppl 6) (2013) vi125-vi132.

Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369 (3) (2013) 213–223.

Pico JL, Rosti G, Kramar A et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing fi rst-line platinum chemotherapy for ad-vanced germ cell tumours. Ann Oncol 16 (2005) 1152–1159.

Pectasides D, Pectasides M, Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Eur Urol 48 (2005) 60–67.

Pico JL, Rosti G, Kramar A et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing fi rst-line platinum chemotherapy for ad-vanced germ cell tumours. Ann Oncol 16 (2005) 1152–1159.

Pienta KJ, Redman B, Hussain M et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12 (1994) 2005–2012.

Pilepich MV, Winter K, John MJ et al. Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to defi nitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1 (50) (2001) 1243–1252.

Redman BG, Smith DC, Flaherty L et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16 (1998) 1844–1848.

Rick O, Bokemeyer C, Weinknecht S et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 22 (2004) 3713–3719.

Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26 (2008) 5422–5428.

Ryan CJ, Smith MR, de Bono JS, COU-AA-302 Investigators. Abiraterone in meta-static prostate cancer without previous chemotherapy. N Engl J Med 368 (2) (2013) 138–148.

Sammler C, Beyer J, Bokemeyer C et al. Risk factors in germ cell tumor patients with relapse or progressive disease after fi rst-line chemotherapy: evaluation of a



prognostic score for survival after high-dose chemotherapy. J Clin Oncol 25 (2008) 2778–2784.

Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012) 1187–1197.

Schmitt B, Wilt TJ, Schellhammer PF et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Uro-logy 57 (2001) 727–732.

Schölermann KH, Dettmann R, Hartmann M. Die risikogesteuerte Hodentumor-nachsorge. Urologe A 35 (1996) 326–330.

Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasi-ve bladder cancer: long-term results in 1054 patients. J Clin Oncol 19 (2001) 666–675.

Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metas-tatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28 (2010) 1061–1068.

Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 351 (2004) 1502–1512.

Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate can-cer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756–1764.

Vaughn DJ, Malkowicz SB, Zoltick B et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 16 (1998) 255–260.

von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068–3077.

White PM, Adamson DJA, Howard GCW. Imaging of the thorax in the manage-ment of germ cell testicular tumours. Clin Radiol 54 (1999) 207–211.

19 Mammakarzinom und gynäkologische Malignome

19.1 MammakarzinomThe Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists‘ Group Ef-fect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast can-cer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45–53.

Badwe R, Parmar V, Hawaldar R. Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at fi rst presentation: A rando-mized controlled trial. Paper presented at: 36th Annual San Antonio Breast Cancer Symposium (2013) Abstract S2–02.

e5319 Mammakarzinom und gynäkologische Malignome


Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366 (2012a) 520–529.

Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366 (2012b) 109–119.

Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with ta-moxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: fi rst results of the ATAC randomised trial. Lancet 359 (2002) 2131–2139.

Bidard FC, Fehm T, Ignatiadis M et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metasta-sis Rev 32 (1–2) (2013) 179–188.

Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, me-thotrexate, and fl uorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332 (1995) 901–906.

Bria E, Nistico C, Cuppone F et al. Benefi t of taxanes as adjuvant chemotherapy for early breast cancer. American Cancer Society. Cancer 106 (11) (2006) 2337–2344.

Cold S, Jensen NV, Brincker H, Rose C. The infl uence of chemotherapy on survival after recurrence in breast cancer – a population-based study of patients treated in the 1950 s, 1960 s and 1970 s. Eur J Cancer 29A (1993) 1146–1152.

Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in ad-juvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28 (3) (2010) 509–518.

Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG). Clarke M, Coates AS, Darby SC et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast can-cer: patient-level meta-analysis of randomised trials. Lancet 371 (9606) (2008) 29–40.

Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG), Darby S, McGale P et al. Eff ect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378 (2011) 1707–1716.

Early Breast Cancer Trialists‘ Collaborative G, Peto R, Davies C et al. Compari-sons between diff erent polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379 (2012) 432–444.

Finn RS, Dieras V, Gelmon KA et al. A randomized, multicenter, double-blind pha-se III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(–) breast cancer who have not received any prior systemic anticancer treatment for advanced disease. J Clin Oncol 31 (2013) (suppl; abstr TPS652).

Fleissig A, Fallowfi eld LJ, Langridge CI et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 95 (3) (2006) 279–293.

Giordano SH, Buzdar AU, Smith TL et al. Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000. Cancer 100 (1) (2004) 44–52.



Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24 (2013) 2206–2223.

Goss PE, Ingle JN, Alés-Martínez JE et al. Exemestane for Breast-Cancer Preventi-on in Postmenopausal Women. N Engl J Med 364 (2011) 2381–2391.

Nabholtz JM. Docetaxel-anthracycline combinations in metastatic breast cancer. Breast Cancer Res Treat 97 (Suppl 1) (2003) 3–9.

Purushotham AD. The diagnosis and management of pre-invasive breast disease: problems associated with management of pre-invasive lesions. Breast Cancer Res 5 (2003) 309–312.

Schmitt M, Mengele K, Gkazepis A et al. Assessment of urokinase-type plasmino-gen activator and its inhibitor PAI-1 in breast cancer tissue: historical aspects and future prospects. Breast Care (Basel) 3 (s2) (2008) 3–10.

Silverstein MJ, Buchanan C. Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. Breast 12 (2003) 457–471.

Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20 (2002) 3628–3636.

Soran A, Ozmen V, Ozbas S. Early follow-up of a randomized trial evaluating re-section of the primary breast tumor in women presenting with de novo stage IV breast cancer. Paper presented at: 36th Annual San Antonio Breast Cancer Sympo-sium (2013) Abstract S2–03.

Ueno NT, Buzdar AU, Singletary SE et al. Combined-modality treatment of in-fl ammatory breast carcinoma: twenty years of experience at M. D. Anderson Can-cer Center. Cancer Chemother Pharmacol 40 (1997) 321–329.

19.2 OvarialtumorenAghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30 (17) (2012) 2039–2045.

Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365 (26) (2011) 2473–2483.

du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfi sterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ova-rialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l‘Ovaire (GINECO). Cancer 115 (6) (2009) 1234–1244.

Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. J Epidemiol Biostat 6 (2001) 107–138.

Katsumata N, Yasuda M, Isonishi S et al. Long-term results of dose-dense paclita-xel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG



3016): a randomised, controlled, open-label trial. Lancet Oncol 14 (10) (2013) 1020–1026.

Ozols RF. Current controversies in ovarian cancer: Maintenance chemotherapy and neoadjuvant chemotherapy as standard care. ASCO educational book (2004) 268–275.

Perren TJ, Swart AM, Pfi sterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365 (26) (2011) 2484–2496.

Pfi sterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecolo-gic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Proc Am Soc Clin Oncol (2004) Abstract 5005.

Pfi sterer J, Plante M, Vergote et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an inter-group trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (29) (2006) 4699–4707.

Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after pro-phylactic oophorectomy in women with a family history of ovarian cancer. A re-port of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71 (1993) 2751–2755.

Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab Combined With Chemo-therapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. J Clin Oncol 32 (13) (2014)1302–1308.

Rebbeck TR, Lynch HT, Neuhausen SL et al. Prevention and Observation of Surgi-cal End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (21) (2002) 1616–1622.

Scholten AN, Smit VT, Beerman H et al. Prognostic signifi cance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 100 (2004) 764–772.

Slayton RE, Park RC, Silverberg SG et al. Vincristine, dactinomycin, and cyclo-phosphamide in the treatment of malignant germ cell tumors of the ovary. A Gyne-cologic Oncology Group Study (a fi nal report). Cancer 15 (2) (1985) 243–248.

Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic fac-tors in patients with ovarian cancer. Obstet Gynecol 101 (2003) 885–891.

Tobacman JK, Greene MH, Tucker MA et al. Intra-abdominal carcinomatosis af-ter prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 2 (1982) 795–797.

Trimbos B, Timmers P, Pecorelli S et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst 102(13) (2010) 982–987.

Trimbos JB, Timmers P. Chemotherapy for early ovarian cancer. Curr Opin Obs-tet Gynecol 16 (2004) 43–48.

Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surge-ry in stage IIIC or IV ovarian cancer. N Engl J Med 363 (10) (2010) 943–953.

Wagner U, Marth C, Largillier R et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs pac-



litaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107 (4) (2012) 588–591.

Wilailak S, Linasmita V, Srisupundit S. Phase II study of high-dose megestrol aceta-te in platinum-refractory epithelial ovarian cancer. Anticancer Drugs 12 (2001) 719–724.

Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev (2001) CD001034.

Winter-Roach BA, Kitchener HC, Lawrie TA. Adjuvant (post-surgery) chemothe-rapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 3 (2012) CD004706.

19.3 ZervixkarzinomAnonymous: Neoadjuvant chemotherapy for locally advanced cervix cancer. Cochrane Database Syst. Rev. (2004) CD001774.

Benedet JL, Bender H, Jones H 3rd et al. FIGO staging classifi cations and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology Int J Gynaecol Obstet 70 (2000) 209–262.

Castellsague X, Bosch FX, Munoz N et al. Male circumcision, penile human papil-lomavirus infection, and cervical cancer in female partners. N Engl J Med 346 (2002) 1105–1112.

Delgado G, Bundy B, Zaino R et al. Prospective surgical-pathological study of di-sease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 38 (1990) 352–357.

González-Martína A, González-Cortijoa L, Carballoc N et al. The current role of neoadjuvant chemotherapy in the management of cervical carcinoma. Gynecologic Oncology 110 (3) (Suppl 2) (2008) S36–S40.

Green J, Kirwan J, Tierney J et al. Concomitant chemotherapy and radiation thera-py for cancer of the uterine cervix. Cochrane Database Syst Rev (2001) CD002225.

Hazelbag S, Kenter GG, Gorter A, Fleuren GJ. Prognostic relevance of TGF-beta(1) and PAI-1 in cervical cancer. Int J Cancer 112 (2004) 1020–1028.

Kjellberg L, Hallmans G, Ahren AM et al. Smoking, diet, pregnancy and oral con-traceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 82 (2000) 1332–1338.

Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in ad-vanced or recurrent endometrial cancer. Cochrane Database Syst Rev (12) (2010) CD007926.

Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papilloma-virus type 16 vaccine. N Engl J Med 347 (2002) 1645–1651.

Long HJ III, Bundy BN, Grendys EC Jr et al. Randomized Phase III Trial of Cispla-tin. With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecolo-gic Oncology Group Study. J Clin Onc 23 (21) (2005) 4626–4633.

National Comprehensive Cancer Network (NCCN). Cervical Cancer. Version 1.2014 (2014). www.nccn.org/professionals/physician_gls/pdf/cervical.pdf (zuletzt am 18.07.2014).



Mandic A, Vujkov T. Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann Oncol 15 (2004) 197–200.

McLellan R, Dillon MB, Woodruff JD et al. Long-term follow-up of stage I cervical adenocarcinoma treated by radical surgery. Gynecol Oncol 52 (1994) 253–259.

Monk BJ, Sill MW, McMeekin DS et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27 (28) (2009) 4649–4655.

Moreno V, Bosch FX, Munoz N et al. Eff ect of oral contraceptives on risk of cervi-cal cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359 (2002) 1085–1092.

Morice P, Piovesan P, Rey A et al. Prognostic value of lymphovascular space inva-sion determined with hematoxylin-eosin staining in early stage cervical carcinoma: results of a multivariate analysis. Ann Oncol 14 (2003) 1511–1517.

Omura GA, Blessing JA, Vaccarello L et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous car-cinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15 (1997) 165–171.

Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12 (1993) 186–192.

Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for re-current cervical cancer. Cancer Treatment Reviews 34 (2008) 603–613.

Peters WA 3rd, Liu PY, Barrett RJ 2nd et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant thera-py after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18 (2000) 1606–1613.

Roden R, Wu T-C. How will HPV vaccines aff ect cervical cancer? Nature Reviews Cancer 6 (2006) 753–763.

Smith JS, Green J, Berrington de Gonzalez A et al. Cervical cancer and use of hor-monal contraceptives: a systematic review. Lancet 361 (2003) 1159–1167.

Syrjanen KJ. Spontaneous evolution of intraepithelial lesions according to the gra-de and type of the implicated human papillomavirus (HPV). Eur J Obstet Gynecol Reprod Biol 65 (1996) 45–53.

Tewari KS, Sill M, Long HJ et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic zervikal cancer: a Phase III randomized trial of the Gyne-cologic Oncology Group. J Clin Oncol 31 (Suppl) (2013) Abstract 3.

Zanetta G, Fei F, Parma G et al. Paclitaxel, ifosfamide and cisplatin (TIP) chemo-therapy for recurrent or persistent squamous-cell cervical cancer. Ann Oncol 10 (1999) 1171–1174.

19.4 EndometriumkarzinomAbeler VM, Kjorstad KE, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer 2 (1992) 9–22.

Aoki Y, Watanabe M, Amikura T et al. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecol Oncol 94 (2004) 333–339.



Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and ute-rine papillary serous carcinoma of the endometrium: comparison of clinicopatholo-gic features and survival. Int J Gynecol Pathol 14 (1995) 30–38.

Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet 83 (Suppl 1) (2003) 79–118.

Deutsche Krebsgesellschaft: Kurzgefasste Interdisziplinäre Leitlinien, 2008. http://www.krebsgesellschaft.de/download/ll_endometriumkarzinom.pdf.

Goff BA, Kato D, Schmidt RA et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 54 (1994) 264–268.

Gupta JK, Chien PF, Voit D et al. Ultrasonographic endometrial thickness for dia-gnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand 81 (2002) 799–816.

Hanf V, Gunthert AR, Emons G. Endometrial cancer. Onkologie 26 (2003) 429–436.

Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in ad-vanced or recurrent endometrial cancer. Cochrane Database Syst Rev (12) (2010) CD007926.

Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of „untreated“ hyperplasia in 170 patients. Cancer 56 (1985) 403–412.

Smith RA, von Eschenbach AC, Wender R et al. American Cancer Society guideli-nes for the early detection of cancer: update of early detection guidelines for prosta-te, colorectal, and endometrial cancers. Also: update 2001 – testing for early lung cancer detection. CA Cancer J Clin 51 (2001) 38–75, quiz 77–80.

Smith-Bindman R, Kerlikowske K, Feldstein VA et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 280 (1998) 1510–1517.

Tabor A, Watt HC, Wald NJ. Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding. Obstet Gynecol 99 (2002) 663–670.

von Minckwitz G, Loibl S, Brunnert K et al. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer – a multicentre, open, controlled, prospectively randomised trial. Eur J Cancer 38 (2002) 2265–227.

20 Tumoren der HautAgarwala SS, Ferri W, Gooding W, Kirkwood JM. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of pati-ents with metastatic melanoma. Cancer 85 (1999) 1979–1984.

Atzpodien J, Neuber K, Kamanabrou D et al. Combination chemotherapy with or without s. c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 86 (2002) 179–184.

Atkins MB, Lee S, Flaherty LE et al. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with ciplatin, vinblastine, dacarbazine (CVD) IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic

e5920 Tumoren der Haut


melanoma (E3695), an ECOG coordinated intergroup trial. Proc Am Soc Clin On-col 22 (2003) 708.

Bajetta E, Di-Leo A, Zampino MG et al. Multicenter randomized trial of dacarba-zine alone or in combination with two diff erent doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 12 (1994) 806–811.

Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Commit-tee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 (2001) 3635–3648.

Chan AD, Essner R, Wanek L, Morton DL. Judging the therapeutic value of lymph node dissections for melanoma. J Am Coll Surg 191 (2000) 16–23.

Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regmine versus dacarbazin in patients with metastatic melanoma. J Clin Oncol 17 (1999) 2745–2751.

Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011) 2507–2516.

Chiarion Sileni V, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti L, Fava-retto AG, Cetto GL, Monfardini S. Phase II randomized study of dacarbazine, car-mustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res. 11 (2001)189–96.

Cocconi G, Bella M, Calabresi F et al. Treatment of metastatic malignant melano-ma with dacarbazine plus tamoxifen. New Engl J Med 327 (1992) 516–523.

Dorval T, Negrier S, Chevreau C et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in pati-ents with metastatic melanoma: a Federation Nationale des Centres de Lutte Cont-re le Cancer Multicenter, parallel study. Cancer 85 (1999) 1060–1066.

Eggermont AM, Suciu S, Santinami M et al. for the EORTC Melanoma Group (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alo-ne in resected stage III melanoma: fi nal results of EORTC 18991, a randomised phase III trial. Lancet 372 (2008) 117–126.

Eton O, Legha S, Bedikian A et al. Sequential biochemotherapy versus chemothera-py for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20 (2002) 2045–2052.

Falkson CI, Falkson G, Falkson HC. Improved results with the addition of recom-binant interferon alpha-2b to dacarbazine in treatment of patients with metastatic malignant melanoma. J Clin Oncol 9 (1991) 1403–1408.

Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus da-carbazine with interferon alpha-2b and tamoxifen in patients with metastatic mali-gnant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16 (1998) 1743–1751.

Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367 (2012) 1694–703.

Garbe C, Schadendorf D. Surveillance and follow-up examinations in cutaneous melanoma. Onkologie. 26 (2003) 241–6.



Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon alpha-2b as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 351 (1998) 1905–1910.

Hauschild A, Garbe C, Stolz W et al. Dacarbazine and interferon-alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 84 (2001) 1036–1042.

Hauschild A, Weichenthal M, Balda BR et al. Prospective randomized trial of inter-feron alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 21 (2003) 2883–2888.

Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Pac-litaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. J Clin Oncol 27 (2009) 2823–2830.

Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380 (2012) 358–365.

Jacquillat C, Khayat D, Banzet P et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 66 (2001)1873–8.

Johnston SR, Constenla DO, Moore J et al. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or wit-hout interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 77 (1998) 1280–1286.

Jungnelius U, Ringborg U, Aamdal S et al. Dacarbazine-vindesine versus dacarbazi-ne-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur J Cancer 34 (1998) 1368–1374.

Keilholz U, Goey SH, Punt CJ et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Or-ganization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15 (1997) 2579–2588.

Keilholz U, Punt CJ, Gore M et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18.951) of the European Organisation for Research and Treatment of Cancer Me-lanoma Group. J Clin Oncol 23 (2005) 6747–6755.

Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alfa-2b signifi -cantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: results of inter-group trial E1694. J Clin Oncol 19 (2001) 2370–2380.

Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozo-lomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18 (2000) 158–166.

Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomi-de versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47 (2011) 1476–1483.

e6121 Malignome der Weichteile und der Knochen


Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previ-ously untreated metastatic melanoma. N Engl J Med 364 (26) (2011) 2517–2526.

Ridolfi R, Chiarion-Seleni V, Guida M et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpa-tients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20 (2002) 1600–1607.

Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17 (1999) 968–975.

Rusthoven JJ, Quirt IC, Iscoe NA et al. Randomized, double-blind, placebo-cont-rolled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Can-cer Institute of Canada Clinical Trials Group. J Clin Oncol 14 (1996) 2083–2090.

Sparano J, Fisher R, Sunderland M et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon-alfa-2a in patients with advanced melanoma. J Clin Oncol 11 (1993) 1969–1977.

Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012) 2443–2454.

21 Malignome der Weichteile und der KnochenAntman K, Crowley J, Balcerzak SP et al. An Intergroup phase III randomized stu-dy of doxorubicin and dacarbacine with or without ifosfamide and mesna in ad-vanced soft tissue and bone sarcomas. J Clin Oncol 11 (1993) 1276–1285.

Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a rando-mized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumours expressing KIT. J Clin Oncol 26 (2008) 620–625.

Blay J-Y, Le Cesne A, Ray-Coquard I et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tu-mours comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25 (2007) 1107–1113.

DeLaney TF, Spiro IJ, Suit HD et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 56 (2003) 1117–1127.

DeMatteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, dou-ble-blind, placebo-controlled trial. Lancet 28 (2009) 1097–1104.

Demetri GD, van Oosterom AT, Garrett CR et al. Effi cacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329–1338.

Demetri GD, Reichardt P, Kang YK et al. Effi cacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib



(GRID): an international, multicentre, randomised, placebo-controlled, phase 3 tri-al. Lancet 9863 (2013) 295–302.

Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1 (1993) 1269–1275.

Eilber FC, Rosen G, Eckardt J et al. Treatment-induced pathologic necrosis: a pre-dictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 19 (2001) 3203–3209.

ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tu-mors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (Suppl 7) (2012) vii49–55.

Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (Eds.) WHO Classifi ca-tion of Tumours of Soft Tissue and Bone. IARC: Lyon 2013

Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized co-operative trial. J Clin Oncol 19 (2001) 1238–1247.

Fuchs N, Bielack SS, Epler D et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group‘s protocol COSS-86 of intensive multi-drug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9 (1998) 893–899.

Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointes-tinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28 (2010) 1247–1253.

Hartmann JT, Oechsle K, Mayer F et al. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 23 (2003) 1899–1901.

Issels RD, Lindner LH, Verweij J et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 11 (2010) 561–570.

Italiano A, Delva F, Mathoulin-Pelissier S et al. Eff ect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol 12 (2010) 2436–2441.

Joensuu H, Eriksson M, Sundby Hall K et al. One vs three years of adjuvant imati-nib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 12 (2012a) 1265–1272.

Joensuu H, Vehtari A, Riihimäki J et al. Risk of recurrence of gastrointestinal stro-mal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 3 (2012b) 265–274.

Judson I, Verweij J, Gelderblom H et al. Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as fi rst line chemotherapy for patients with advanced or metastatic soft tissue sarco-ma: A survival study by the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 23 (2012) (suppl 9) ixe28.

Kager L, Zoubek A, Potschger U et al. Primary metastatic osteosarcoma: presenta-tion and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma

e6321 Malignome der Weichteile und der Knochen


Study Group protocols. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. J Clin Oncol 21 (2003) 2011–2018.

Ladenstein R, Pötschger U, Cécile M et al. Primary disseminated multifocal Ewing sarcoma: Results of the Euro-EWING 99 trial. J Clin Oncol 28 (2010) 3284–3291.

Le Cesne A, Blay J-Y, Judson I et al. Phase II study of ET-743 in advanced soft tis-sue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23 (2005) 576–584.

Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration stu-dy 002. J Clin Oncol 25 (2007) 2755–2763.

Mastrangelo G, Coindre JM, Ducimetière F et al. Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. Cancer 21 (2012) 5339–5348.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at diff erent sites. Semin Diagn Pathol 23 (2006) 70–83.

Patrikidou A, Chabaud S, Ray-Coquard I et al. Infl uence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann On-col 4 (2013) 1087–1093.

Paulussen M, Ahrens S, Dunst J et al. Localized Ewing tumor of bone: fi nal results of the cooperative Ewing‘s Sarcoma Study CESS 86. J Clin Oncol 19 (2001) 1818–1829.

Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta-analysis of rando-mized controlled trials of adjuvant chemotherapy for localized resectable soft-tis-sue sarcoma. Cancer 113 (2008) 573–581.

Reichardt P, Tilgner J, Hohenberger P, Dörken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and fi lgrastim for adult patients with metastatic or lo-cally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 16 (1998) 1438–1443.

Reichardt P, Blay JY, Boukovinas I et al. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol 11 (2012) 2776–2781.

Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localised resec-table soft tissue sarcoma in adults. Cochrane Database Syst Rev 4 (2000).

Saylors RL, Stine KC, Sullivan J et al. Cyclophosphamide plus topotecan in child-ren with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19 (2001) 3463–3469.

Schlemmer M, Reichardt P, Verweij J et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 16 (2008) 2433–2436.

Sobin LH, Gospadarowicz MK, Wittekind C (eds.): UICC: TNM classifi cation of malignant tumors. 7th Edition, John Wiley & Sons, New York 2009.

Trojani M, Contesso G, Coindre JM et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and defi nition of a histopathological grading sys-tem. Int J Cancer 33 (1984) 37–42.



van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 tri-al. Lancet 379 (2012) 1879–1886.

van Oosterom AT, Mouridsen HT, Nielsen OS et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two diff erent ifosfamide regimens in fi rst- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 38 (2002) 2397–2406.

Verweij J, Casali P, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127–1134.

Wagner LM, McAllister N, Goldsby RE et al. Temozolomide and intravenous iri-notecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2 (2007) 132–139.

Woll PJ, Reichardt P, Le Cesne A et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 10 (2012) 1045–1054.

Zalcberg JR, Verveij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41 (2005) 1751–1757.

22 Malignome endokriner Organe

22.1 SchilddrüsenkarzinomAhuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10 (1987) 303–310.

AJCC Cancer Staging Manual, Seventh Edition, (2010), Springer Verlag, New York, Inc.

Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Ana-plastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10 (2000) 587–594.

Bajetta E, Zilembo N, Di Bartolomeo M et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer 72 (1993) 3099–3105.

Brierley JD, Tsang RW. External radiation therapy in the treatment of thyroid ma-lignancy. Endocrinol Metab Clin North Am 25 (1996) 141–157.

Casara D, Rubello D, Saladini G et al. Distant metastases in diff erentiated thyroid cancer: Long-term results of radioiodine treatment and statistical analysis of prog-nostic factors in 214 patients. Tumori 77 (1991) 432–436.

Casara D, Rubello D, Saladini G et al. Diff erent features of pulmonary metastases in diff erentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34 (1993) 1626–1631.

e6522 Malignome endokriner Organe


Chatal JF, Campion L, Kraeber-Bodere F et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryo-nic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24 (11) (2006) 1705–1711.

Cooper DS, Specker B, Ho M et al. Thyrotropin suppression and disease progressi-on in patients with diff erentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8 (1998) 737–744.

De Besi P, Busnardo B, Toso S et al. Combined chemotherapy with bleomycin, ad-riamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14 (1991) 475–480.

Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carci-noma. A population-based study of 15.698 cases from the Surveillance, Epidemiolo-gy and Results (SEER) program, 1973–1991. Cancer 79 (1997) 564–573.

Gottlieb JA, Hill, CS Jr. Chemotherapy of thyroid cancer with adriamycin. N Engl J Med 290 (4) (1974) 193–197.

Gupta-Abrahamson V, Troxel AB, Nellore A e t al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26 (2008) 4714–4719.

Hay ID, Bergstralh EJ, Goellner JR et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114 (1993) 1050–1057.

Jemal A, Simard EP, Dorell C et al. Annual Report to the Nation on the Status of Cancer, 1975–2009. J Natl Cancer Inst 105 (3) (2013) 175.

Kebebew E, Greenspan FS, Clark OH et al. Anaplastic thyroid carcinoma. Treat-ment outcome and prognostic factors. Cancer 103 (2005) 1330–1335.

Ladenson PW, Braverman LE, Mazzaferri EL et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radio-active iodine scanning in patients with thyroid carcinoma. N Engl J Med 337 (1997) 888–896.

Lupoli G, Cascone E, Arlotta F et al. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer 78 (1996) 1114–1118.

Mahler C, Verhelst J, de Longueville M, Harris A. Long-term treatment of metas-tatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 33 (1990) 261–269.

Malchoff CD, Ross DS, Mulder JE. Oncogenes and tumor suppressor genes in thy-roid nodules and nonmedullary thyroid cancer. UpToDate 18.3.2010, www.upto-date.com.

McIver B, Hay ID, Giuff rida DF et al. Anaplastic thyroid carcinoma: a 50-year ex-perience at a single institution. Surgery 130 (2001) 1028–1034.

Orlandi F, Caraci P, Berruti A et al. Chemotherapy with dacarbazine and 5-fl uo-rouracil in advanced medullary thyroid cancer. Ann Oncol 5 (1994) 763–765.

Polednak AP. Trends in cancer incidence in Connecticut, 1935–1991. Cancer 74 (1994) 2863–2872.



Samaan NA, Schultz PN, Hickey RC et al. The results of various modalities of treatment of well diff erentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75 (1992) 714–720.

Shimaoka K, Schoenfeld DA, DeWys WD et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56 (1985) 2155–2160.

Tsang RW, Brierley JD, Simpson WJ et al. The eff ect of surgery, radioactive iodine and external radiation therapy on the clinical outcome of patients with diff erentia-ted thyroid carcinoma. Cancer 82 (1998) 375–388.

Tuttle RM, Ross DS, Mulder JE. Overview of the management of diff erentiated thyroid cancer. UpToDate 18.3.2010, www.uptodate.com.

Voutilainen PE, Multanen MM, Leppaniemi AK et al. Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 11 (2001) 953–957.

Wells SA Jr, Robinson BG, Gagel, RF et al. Vandetanib in patients with locally ad-vanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30 (2) (2012) 134.

22.2 Tumoren der NebenniereAverbuch SD, Steakley CS, Young RC et al. Malignant pheochromocytoma: eff ec-tive treatment with a combination of cyclophosphamide, vincristine, and dacarba-zine. Ann Intern Med 109 (1988) 267–273.

Ayala-Ramirez M, Chougnet CN, Habra MA et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic para-gangliomas. J Clin Endodrinol Metab 97 (11) (2012) 4040–4045.

Dunnick NR, Korobkin M, Francis I. Adrenal radiology: distinguishing benign from malignant adrenal masses. AJR Am J Roentgenol 167 (1996) 861–867.

Haak HR, Hermans J, van de Velde CJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69 (1994) 947–951.

Fassnacht M, Terzolo M, Allolio B et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366 (23) (2012) 2189–2197.

Forrer F, Riedweg I, Maecke HR et al. Radiolabeled DOTATOC in patients with advanced paraganglioma andpheochromocytoma. Q J Nucl Med Mol Imaging 52 (4) (2008) 334–340.

Huang H, Abraham J, Hung E et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommen-dation from a 22-year follow-up of 18 patients. Cancer 113(8) (2008) 2020–2028.

Krempf M, Lumbroso J, Mornex R et al. Use of m-(J131)iodobenzylguanidine in the treatment of malignant pheochromocytome. J Clin Endocrinol Metab 72 (1991) 455–461.

Loh KC, Fitzgerald PA, Matthay KK et al. The treatment of malignant pheochro-mocytoma with iodine-131-metaiodobenzylguanidine(131I-MIBG): a comprehensi-ve review of 116 reported patients. J Endocrinol Invest 20 (11) (1997) 648–658.



Taieb D, Sebag F, Hubbard JG et al. Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phechromocytoma? Clin Endocrinol (Oxf.) 61 (2004) 102–108.

Terzolo M, Angeli A, Fassnacht M et al. Adjuvant mitotane treatment for adre-nocortical carcinoma. N Engl J Med 356 (23) (2007) 2372–2380.

22.3 Neuroendokrine Neoplasien (NEN) des gastroenteropankreatischen Systems

Arnold R, Trautmann ME, Creutzfeldt W et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38 (1996) 430–438.

Breeman WA, de Jong M, Kwekkeboom D et al. Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future per-spectives. Eur J Nucl Med 28 (2001) 1421–1429.

Bushnell DL, O‘Dorisio TM, O‘Dorisio MS et al. 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide. J Clin Oncol 28 (2010) 1652–1659.

Caplin ME, Pavel M, Ćwikła JB et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371 (3) (2014) 224–233.

Caplin M, Ruszniewski P, Pavel M et al. A randomized, double-blind, placebo-controlled study of Lanreotide Antiproliferative Response in patients with gastro-enteropancreatic NeuroEndocrine Tumors (CLARINET). Presented at ECC 2013. Abstract LBA3.

Carney JA. Familial multiple endocrine neoplasia syndromes: Components, classi-fi cation, and nomenclature. J Int Med 243 (1998) 425–432.

Ekeblad S, Sundin A, Tiensuu Janson E et al. Temozolomide as Monotherapy Is Eff ective in Treatment of Advanced Malignant Neuroendocrine Tumors. Clin Can-cer Res 13 (2007) 2986–2990.

Ekeblad S, Skogseid B, Dunder K et al. Prognostic factors and survival in 324 pati-ents with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14 (2008) 7798–7803.

Ezzidin S, Opitz M, Attasi M et al. Impact of the Ki-67 proliferation index on res-ponse to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging (2010) (published online).

Faiss S, Pape UF, Böhmig M et al. Prospective, randomized, multicenter trial on the antiproliferative eff ect of lanreotide, interferon-alfa, and their combination for the-rapy of metastatic neuroendocrine gastroenteropancreatic tumors – The Internati-onal Lanreotide and Interferon-alfa Study Group. J Clin Oncol 21 (2003) 2689–2696.

Falconi M, Bartsch DK, Eriksson B et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-diff erentiated pancreatic non-functioning tumors. Neuroendocrinolo-gy 95 (2012) 120–134.

Hentic O, Hammel P, Couvelard A et al. FOLFIRI regimen: an eff ective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 19 (2012) 751–757.



Imhof A, Brunner P, Marincek N et al. Response, Survival, and Long-Term Toxici-ty After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. J Clin Oncol 29 (2011) 2416–2423.

Jann H, Roll S. Couvelard A et al. Neuroendocrine tumors of mid- and hindgut origin: TNM-classifi cation determines clinical outcome. Cancer 117 (2011) 3332–3341.

Jensen RT, Cadiot G, Brandi ML et al. ENETS Consensus Guidelines for the ma-nagement of patients with digestive neuroendocrine neoplasms: functional pan-creatic endocrine tumor syndromes. Neuroendocrinology 952 (2012) 98–119.

Klimstra DS, Modlin IR, Adsay NV et al. Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a mini-mum pathology data set. Am J Surg Pathol 34 (2010) 300–313.

Chan JA, Stuart K, Earle CC et al. Prospective study of bevacizumab plus temozo-lomide in patients with advanced neuroendocrine tumors. J Clin Oncol 30 (2012) 2963–2968.

Kwekkeboom DJ, deHerder WW, Kam BL et al. Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Effi cacy, and Survival. J Clin Oncol 26 (2008) 2124–2130.

La Rosa S, Klersy C, Uccella S et al. Improved histologic and clinicopathologic cri-teria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 401 (2009) 30–40.

Marlink RG, Lokich JJ, Robins JR et al. Hepatic arterial embolization for metasta-tic hormone-secreting tumors: Technique, eff ectiveness, and complications. Cancer 65 (1990) 2227–2232.

Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Can-cer 97 (2003) 934–959.

Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tu-mours. Lancet Oncol 9 (2008) 61–72.

Moertel CG. An Odyssey in the land of small tumors. J Clin Oncol 5 (1987) 1503–1522.

Moertel CG, Kvols LK, O‘Connel MJ et al. Treatment of neuroendocrine carcino-mas with combined etoposide and cisplatin. Cancer 68 (1991) 227–232.

Moertel CG, Lefkopoulo M, Lipsitz S et al. Streptozotocin-doxorubicin, streptozo-tocin-fl uorouracil or chlorozotocin in the treatment of advanced islet cell carcino-ma. N Engl J Med 326 (1992) 519–523.

Moller JE, Connolly HE, Rubin J et al. Factors associated with progression of car-cinoid heart disease. N Engl J Med 348 (2003) 1005–1015.

Öberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancrea-tic system. Ann Oncol 15 (2004) 966–973.

Öberg K, Knigge U, Kwekkeboom D et al. Neuroendocrine gastro-entero-pancrea-tic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 (Suppl 7) (2012) vii124–130.

Otte A, Mueller-Brand J, Dellas S et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351 (1998) 417–418.



Pape UF, Jann H, Müller-Nordhorn J et al. Prognostic relevance of a novel TNM classifi cation system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113 (2008) 256–265.

Pape UF, Perren A, Niederle B et al. ENETS Consensus Guidelines for the manage-ment of patients with neuroendocrine neoplasms from the jejuno-ileum and the ap-pendix including goblet cell carcinomas. Neuroendocrinology 95 (2012) 135–156.

Pavel M, Baudin E, Couvelard A et al. ENETS Consensus Guidelines for the ma-nagement of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinolo-gy 95 (2012) 157–176.

Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 stu-dy. Lancet 378 (2011) 2005–2012.

Plöckinger U, Rindi G, Arnold R et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology 80 (2005) 394–424.

Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pan-creatic neuroendocrine tumors. N Engl J Med 364 (2011) 501–513.

Rindi G, Klöppel G, Ahlmann H et al. TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch 449 (2006) 395–401.

Rindi G, Klöppel G, Couvelard A et al. TNM staging of midgut and hindgut (neu-ro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451 (2007) 757–762.

Rinke A, Müller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the eff ect of octreotide LAR in the control of tu-mor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27 (2009) 4656–4663.

Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117 (2010) 268–275.

Yao JC, Hassan M, Phan A et al. One hundred years after „carcinoid“: epidemiolo-gy of and prognostic factors for neuroendocrine tumors in 35,825 cases in the Uni-ted States. J Clin Oncol 26 (2008) 3063–3072.

Yao JC, Phan AT, Chang DZ et al. Effi cacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26 (2008) 4311–4318.

Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in pati-ents with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (2010) 69–71.

Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 (2011) 514–523.



23 Malignome unbekannter PrimärlokalisationAssersohn L, Norman AR, Cunningham D et al. A randomised study of protracted venous infusion of 5-fl uorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. Eur J Cancer 39 (2003) 1121–1128.

Dova L, Pentheroudakis G, Golfi nopoulos V et al. Targeting c-KIT, PDGFR in can-cer of unknown primary: a screening study for molecular markers of benefi t. J Can-cer Res Clin Oncol 134 (2008) 697–704.

Germer C-T, Sweeney RA, Melcher I et al. Management des CUP-Syndroms mit Oligometastasierung. Der Onkologe 14 (2008) 908–919.

Greco FA, Erland JB, Morrissey LH et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11 (2000) 211–215.

Greco FA, Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 36 (2009) 65–74.

Hainsworth JD, Erland JB, Kalman LA et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol, 15 (1997) 2385–2393.

Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol 36 (2009) 44–51.

Hainsworth JD, Spigel DR, Farley C et al. Phase II trial of bevacizumab and erloti-nib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Net-work. J Clin Oncol 25 (2007) 1747–1752.

Hainsworth JD, Spigel DR, Thompson DS et al. Paclitaxel/Carboplatin plus beva-cizumab/erlotinib in the fi rst-line treatment of patients with carcinoma of unknown primary site. Oncolotist 14 (12) (2009)1189–1197.

Hainsworth JD, Spigel DR, Howard AB et al. Oxaliplatin and capecitabine in the treatment of patients with recurrence or refractory carcinoma of unknown primary site. Cancer 116 (2010) 2448–2452.

Huebner G, Bokemeyer C. CUP-Syndrom – Tumorerkrankung mit unbekanntem Primärtumor. Deutsche Gesellschaft für Hämatologie und Onkologie, Thera-pieleitlinien, online (2005).

Huebner G, Link H, Kohne CH et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undiff erentiated carcinoma of unknown pri-mary: a randomised prospective phase II trial. Br J Cancer 100 (2009) 44–49.

Huebner G. Prognoseklassifi kation beim CUP-Syndrom. Der Onkologe 14 (2008) 892–897.

Kretzschmar A. Prognoseadaptierte Therapie beim fortgeschrittenen CUP-Syn-drom. Der Onkologe 14 (2008) 920–930.

Lobins R, Floyd J. Small cell carcinoma of unknown primary. Semin Oncol 34 (2007) 39–42.

Mozet C, Wuttke P, Bertolini J et al. Zervikale und axillare Metastasen unbekann-ten Ursprungs. Der Onkologe 14 (2008) 898–907.

e7124 Malignome des zentralen Nervensystems (ZNS)


Neben K, Huebner G, Folprecht G et al. Metastasen ohne Primärtumor. Deutsches Aerzteblatt 105 (2008) 733–740.

Palmeri S, Lorusso V, Palmeri L et al. Cisplatin and gemcitabine with either vino-relbine or paclitaxel in the treatment of carcinomas of unknown primary site : re-sults of an Italian multicenter, randomized, phase II study. Cancer 107 (2006) 2898–2905.

Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol He-matol 69 (3) (2009) 271–278.

Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 46 (2007) 592–601.

Pentheroudakis G, Pavlidis N. Perspectives for targeted therapies in cancer of un-known primary site. Cancer Treat Rev 32 (2006) 637–644.

Polyzoidis KS, Miliaras G, Pavlidis N. Brain metastasis of unknown primary: a dia-gnostic and therapeutic dilemma. Cancer Treat Rev 31 (2005) 247–255.

Pouessel D, Culine S, Becht C et al. Gemcitabine and docetaxel after failure of cis-platin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res 23 (2003) 2801–2804.

Schneider BJ, El-Rayes B, Muler JH et al. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer 110 (2007) 770–775.

Seve P, Billotey C, Broussolle C et al. The role of 2-deoxy-2-[F-18]fl uoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary si-te. Cancer 109 (2007) 292–299.

Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown pri-mary site. Semin Oncol 36 (2008) 52–59.

Varadhachary GR, Greco FA. Overview of patient management and future direc-tions in unknown primary carcinoma. Semin Oncol 36 (2009) 75–80.

Varadhachary GR, Talantov D, Raber MN et al. Molecular profi ling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26 (2008) 4442–4448.

Wittekind C, Horn L-C. Pathohistologische und molekulargenetische Diagnostik beim CUP-Syndrom. Der Onkologe 14 (2008) 870–878.

24 Malignome des zentralen Nervensystems (ZNS)

Barlesi F, Gervais R, Lena H et al. Pemetrexed and cisplatin as fi rst line chemothe-rapy for advanced non-small-cell lung cancer with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 087–01). Ann Oncol 22 (2011) 2466–2470.

Brada M, Stenning S, Gabe R et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high grade glioma. J Clin Oncol 28 (2010) 4601–4608.



Buckner JC, Brown PD, O‘Neill BP et al. Central nervous system tumors. Mayo Clin Proc 82 (2001) 1271–1286.

Caff o M, Barresi V, Caruso G et al. Innovative therapeutic strategies in the treat-ment of brain metastases. Int J Mol Sciences 14 (2013) 2135–2174.

Chinot O, Macdonald DR, Abrey LE et al. Response assessment criteria for glio-blastoma: practical adaptation and implementation in clinical trials of antiangioge-nic therapy. Curr Neurol Neurosci Rep 13 (2013) 347–360.

Comte A, Jdid W, Guilhaume MN et al. Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J Neurooncol 115 (2013) 445–452.

Dudel C, Siefert A. Lymphome. In: Tonn JC, Kreth FW, Goldbrunner R, Meyer B: Manual Hirntumoren und spinale Tumoren. 3. Aufl . Zuckschwerdt Verlag, Mün-chen (2007) 155–159.

Fonkem E, Uhlmann EJ, Floyd SR et al. Melanoma brain metastases: overview of current management and emerging targeted therapies. Expert Rev Neurother 12 (2012) 1207–1215.

Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 28 (2009) 4733–4740.

Gilbert MR et al. Annual Meeting of the American Society of Clinical Oncology (ASCO). (2013) Abstract #1.

Gil-Gil MJ, Mesia C, Rey M et al. Bevacizumab for the treatment of glioblastoma. Clinical Medicine Insights. Oncology 7 (2013) 123–135.

Grosu AL, Deckert-Schmitz M, Astner ST et al. Hirnmetastasen und Meningeosis carcinomatosa. In: Tonn JC, Kreth FW, Goldbrunner R, Meyer B. Manual Hirntu-moren und spinale Tumoren. 3. Aufl . Zuckschwerdt Verlag, München (2007) 146–154.

Huynh CG, Chen A, Fehrenbacher L et al. Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer 9 (2008) 35–38.

James CD, Louis DN, Cavenee WK. Molecular biology of the central nervous sys-tem. In: DeVita Jr VT, Lawrence TS, Rosenberg SA (eds): Cancer – principles and practice of oncology, 8th ed. Wolters Kluwer, Lippincott, Williams & Wilkins, Philadelphia (2008) 1967–1975.

Johnson DR, Leeper HE, Uhm JH. Glioblastoma survival in the United States im-proved after Food and Drug Administration approval of bevacizumab: a populati-on based analysis. Cancer 119 (2013) 3489–3495.

Kleihues P, Cavenee WK. Pathology and genetcis of tumors of the nervous system. IARC Press, Lyon (2000).

Krauseneck P, Kortmann RD, Schmoll HJ. Primäre Hirntumoren bei Erwachsenen. In: Schmoll HJ, Höff ken K, Possinger K: Kompendium Internistische Onkologie, 3. Aufl . Vol. 2. Springer Berlin (1999) 475–523.

Kreisl TN, Kim L, Moore K et al. Phase II trial of single agent bevacizumab follo-wed by bevacizumab plus irinotecan at tumor progression in recurrent glioblasto-ma. J Clin Oncol 27 (2009) 740–745.

Kreth FW. Mikrochirurgische und stereotaktische Therapieoptionen im Behand-lungskonzept der Gliome. Krebsmedizin 19 (2010) 171–180.

e7324 Malignome des zentralen Nervensystems (ZNS)


Laigle-Donadey F, Figarella-Branger D, Chinot O et al. Up front temozolomide in elderly patients with glioblastoma. J Neurooncol 99 (2010) 89–94.

Larson DA, Rubenstein JL, McDermott MW. Metastatic Cancer to the brain. In: DeVita Jr VT, Lawrence TS, Rosenberg SA (eds): Cancer – principles and practice of oncology, 8th ed. Wolters Kluwer, Lippincott, Williams & Wilkins, Philadelphia (2008) 2461–2475.

Linn J. Schnittbilddiagnostik der Hirntumoren. Krebsmedizin 19 (2010) 162–170.

Lumenta B, Wowra B, Grosu AL, Goldbrunner R. Neurinome. In: Tonn JC, Kreth FW, Goldbrunner R, Meyer B: Manual Hirntumoren und spinale Tumoren. 3. Aufl . Zuckschwerdt Verlag, München (2007) 137–145.

Mehta MP, Buckner JC, Sawaya R et al. Neoplasms of the central nervous system. In: DeVita Jr VT, Lawrence TS, Rosenberg SA (eds): Cancer – principles and practice of oncology, 8th ed. Wolters Kluwer, Lippincott, Williams & Wilkins, Phi-ladelphia (2008) 1975–2031.

Meyer B, Goldbrunner R, Ringel F et al. Höhergradige Gliome und Gliomatosis cerebri. In: Tonn JC, Kreth FW, Goldbrunner R, Meyer B: Manual Hirntumoren und spinale Tumoren. 3. Aufl . Zuckschwerdt Verlag, München (2007) 92–101.

Mirimanoff RO, Gorlia T, Mason W et al. Radiotherapy for newly diagnosed glio-blastoma: Recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24 (2006) 2563–2569.

Niyazi M, Ganswindt U, Schwarz SB et al. Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 82 (2012) 67–76.

Nonomura N, Nagahara A, Oka D et al. Brain metastases from testicular germ cell tumors: a retrospective analysis. Int J Urol 16 (2009) 887–893.

Olson JJ, Paleologos NA, Gaspar LE et al. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clini-cal practice guideline of selected topics. J Neurooncol 96 (2010) 115–142.

Ono M, Ando M, Yunokawa M et al. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol 14 (2009) 48–52.

Peraud A, Kreth FW, Meyer B et al. Niedermaligne Gliome. In: Tonn JC, Kreth FW, Goldbrunner R, Meyer B: Manual Hirntumoren und spinale Tumoren. 3. Aufl . Zuckschwerdt Verlag, München (2007) 86–91.

Reveiz L, Rueda JR, Caradona AF. Chemotherapy for brain metastases from small cell lung cancer. Cochrane Database Syst Rev (2012) 6:CD007464.

Schaaf L, Uhl E, Schopohl J et al. Hypophysentumren und Kraniopharyngeome. In: Tonn JC, Kreth FW, Goldbrunner R, Meyer B: Manual Hirntumoren und spinale Tumoren. 3. Aufl . Zuckschwerdt Verlag, München (2007) 114–124.

Schalhorn A. Stellenwert der Chemotherapie bei malignen Hirntumoren. Krebsme-dizin 19 (2010) 194–199.

Schlegel J, Herms J. WHO-Klassifi kation der Tumoren des Nervensystems. In: Tonn JC, Kreth FW, Goldbrunner R, Meyer B: Manual Hirntumoren und spinale Tumoren. 3. Aufl . Zuckschwerdt Verlag, München (2007) 2–16.

Schmid I, Peraud A, Pöllinger B. Kindliche Tumoren. In: Tonn JC, Kreth FW, Goldbrunner R, Meyer B: Manual Hirntumoren und spinale Tumoren. 3. Aufl . Zuckschwerdt Verlag, München (2007) 102–113.



Schouten LJ, Rutten J, Huveners HA et al. Incidence of brain metastases in a cohort of patients with carcinomas of breast, colon, kidney, and lung and melanoma. Can-cer 94 (2002) 2698.

Seute T, Leff ers P, Wilmink JT et al. Response of asymptomatic brain metastases from small-cell lung cancer to systemic fi rst line therapy. J Clin Oncol 24 (2006) 2079–2083.

Siefert A, Thon N, Kreth FW. Strahlentherapie bei Hirntumoren. Krebsmedizin 19 (2010) 189–194.

Stewart A. Glioma Meta-analysis Trialists (GMT) Group: Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient da-ta from 12 randomized trials. Lancet 359 (2002) 1011–1018.

Stupp R, Hegi ME, Mason WP et al. Eff ects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet On-col 10 (2009) 459–466.

Sutherland S, Ashley S, Miles D et al. Treatment of HER2-positve metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access program-me, including effi cacy in brain metastases – the UK experience. Br J Cancer 102 (2010) 995–1002.

Thon N, Muacevic A, Siefert A, Rachinger W. Stellenwert der Operation bei intra-kraniellen Meningeomen, Metastasen und Hypophysentumoren. Krebsmedizin 19 (2010) 189–193.

Tonn JC, Kreth FW, Goldbrunner R, Meyer B. Manual Hirntumoren und spinale Tumoren. 3. Aufl . W. Zuckschwerdt Verlag, München (2007).

van den Bent MJ, Brandes AA, Rampling R et al. Randomized phase II trial of erlo-tinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group study 26.034. J Clin Oncol 27 (2009a) 1268–1274.

van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomus-tine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A rando-mized EORTC phase III trial. J Clin Oncol 24 (2006) 2715–2722.

van den Bent MJ, Dubbink HJ, Marie Y et al. IDH1 and IDH2 mutations are prog-nostic but not predictive for outcome in anaplastic oligodendroglial tumors: a re-port of the EORTC Brain Tumor Group. Clin Cancer Res 16 (2010) 1597–1604.

van den Bent MJ, Dubbink HJ, Sanson M et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in ana-plastic oligendendroglial tumors: a report from EORTC Brain Tumor Group study 26.951. J Clin Oncol 27 (2009b) 5881–5887.

Vredenburgh JJ, Desjardins A, Herndon JWE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 (2007) 4722–4729.

Wang P, Piao Y, Zhang X et al. The concentration of CYFRA21–1, NSE and CEA in cerebro-spinal fl uid can be useful indicators for diagnosis of meningeal carcino-matosis of lung cancer. Cancer Biomark 13 (2013) 123–130.

Weller M, Felsberg J, Hartmann C et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective

e7525 HIV-assoziierte Malignome


translational study of the German Glioma Network. J Clin Oncol 27 (2009) 5743–5750.

Weller M. Tumoren des Zentralnervenssystems In: Petrasch S, Ehninger G (Hrsg). Update Hämatologie/Onkologie 2010, Lukon Verlag München (2010) 555–568.

Wick W, Hartmann C, Engel C et al. NOA-04 Randomized phase III trial of se-quential radiotherapy of anaplastic glioma with procarbazine, lomustine, and vin-cristine or temozolomide. J Clin Oncol 35 (2009) 5874–5880.

Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin com-pared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28 (2010a) 1168–1174.

Wick W, Weller M, van den Bent M, Stupp R. Bevacizumab and recurrent malig-nant gliomas: A European perspective. J Clin Oncol 28 (2010b) e188–e189.

Winkler PA, Uhl E, Lehmberg J et al. Meningeome und Meningeomatosis. In: Tonn JC, Kreth FW, Goldbrunner R, Meyer B: Manual Hirntumoren und spinale Tumo-ren. 3. Aufl . Zuckschwerdt Verlag, München (2007) 130–136.

Xu T, Chen J, Lu Y et al. Eff ects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survi-val-gain analysis. BMC Cancer 10 (2010) 252.

25 HIV-assoziierte MalignomeAssociation of cancer with AIDS-related immunosuppression in adults. JAMA 285 (2001) 1736–1745.

Bower M. How I treat HIV-associated multicentric Castleman disease. Blood 116 (22) (2010) 4415–4421.

Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-rela-ted immunosuppression in adults. JAMA 285 (13) (2001) 1736–1745.

Gates AE, Kaplan LD. AIDS malignancies in the era of highly active antiretroviral therapy. Oncology Huntingt 16 (2002) 441–451, 456, 459.

Gopal S, Achenbach CJ, Yanik EL, Dittmer DP, Eron JJ, Engels EA. Moving for-ward in HIV-associated cancer. J Clin Oncol 32 (9) (2014) 876–880.

Hentrich M, Hoff mann C, Mosthaf F et al. Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNA), in coope-ration with the German AIDS Society (DAIG). Ann Hematol 93 (6) (2014) 913–921.

Kang EM, de Witte M, Malech H et al. Nonmyeloablative conditioning followed by transplantation of genetically modifi ed HLA-matched peripheral blood progeni-tor cells for hematologic malignancies in patients with acquired immunodefi ciency syndrome. Blood 99 (2002) 698–701.

Krishnan A, Molina A, Zaia J et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 98 (2001) 3857–3859.



Krown SE, Metroka C, Wernz JC. Kaposi‘s sarcoma in the acquired immune defi ci-ency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 7 (1989) 1201–1207.

Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune defi ciency and risk for malignancy among persons with AIDS. J Acquir Immune Defi c Syndr 32 (2003) 527–533.

Ramasamy K, Gandhi S, Tenant-Flowers M et al. Rituximab and thalidomide com-bination therapy for Castleman disease. Br J Haematol 158 (3) (2012) 421–423.

Rossi G, Donisi A, Casari S et al. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodefi ciency virus-related systemic non-Hodgkin lymphoma. Cancer 86 (1999) 2391–2397.

Shiels MS, Pfeiff er RM, Gail MH et al. Cancer burden in the HIV-infected popula-tion in the United States. J Natl Cancer Inst 103 (9) (2012) 753–762.

Tam HK, Zhang YF, Jacobsen LP et al. Eff ect of highly active antiretroviral thera-py on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 98 (2002) 916–922.

The International Non-Hodgkin‘s Lymphoma Prognostic Factors Project: A predic-tive model for aggressive non-Hodgkin‘s lymphoma. The International Non-Hodgkin‘s Lymphoma Prognostic Factors Project. N Engl J Med 329 (1993) 987–994.

Weiss R, Huhn D, Mitrou P et al. HIV-related non-Hodgkin‘s lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy. Leuk Lymphoma 29 (1998) 103–118.

Internetadressenhttp://www.kompetenznetz-leukaemie.de

http://www.lymphome.de

http://www.nccn.org

http://www.kompetenznetz-hiv.de

http://www.hivbuch.de

http://www.hopkins-aids.edu

http://www.hivguidelines.org

26 Hämorrhagische DiathesenBrackmann HH, Depka Prondzinski M, Heinrich C et al. Leitlinien zur Qualitätssi-cherung der Hämophiliebehandlung. Hämostaseologie 30 (2001) 35–36.

Budde U, Drewke E, Will K, Schneppenheim R. Standardisierte Diagnostik des von-Willebrand-Syndroms. Hämostaseologie 24 (2004) 12–26.

Delgado J, Jiminez-Yuste V, Hernandez-Navarro F, Villar A. Acquired hemophi-lia: Review and meta-analysis focused on therapy and prognostic factors. Br J Ha-ematol 121 (2003) 21–35.

e7726 Hämorrhagische Diathesen


Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 1 (2003) 1628–1636.

Colman RW, Hirsh J, Marder VJ et al. Hemostasis and thrombosis. Basic princip-les and clinical practice, 6th ed. Lippincott Williams & Wilkins, Philadelphia 2012.

Dempfl e CE. Coagulopathy of sepsis. Thromb Haemost 91 (2004) 213–224.

Furlan M, Robles R, Galbusera M et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the haemolytic uremic syndrome. N Engl J Med 339 (1998) 1578–1584.

George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicite methods for the American Society of He-matology. Blood 88 (1996) 3–40.

Goodnight SH. Primary vascular disorders. In: Coleman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds): Hemostasis and thrombosis. Basic principles and clinical practice, 4th edn, pp 945–53. Lippincott Williams & Wilkins, Philadelphia 2001.

Hiller E. Thrombopoetin-Rezeptorantagonisten zur Therapie der Immunthrombo-zytopenie. Arzneimitteltherapie 28 (2010) 184–190.

Hiller E, Riess H. Hämorrhagische Diathese und Thrombose. Grundlagen – Klinik – Therapie, 3. Aufl . Wissenschaftliche Verlagsgesellschaft, Stuttgart 2002.

Kaufman DW, Kelly JP, Johannes CB et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 82 (1993) 2714–2718.

Lisman T, DeGrott PHG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 1 (2003) 1138–1139.

Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The fi rst 20 years. Blood 90 (1997) 2515–2521.

Mannucci PM. Treatment of von Willebrand‘s disease. N Engl J Med 351 (2004) 683–694.

Matzdorff A, Giagounidis A, Greinacher A et al. Empfehlungen zur Therapie und Diagnostik der Immunthrombozytopenien. Onkologie 33(suppl 3) (2010) 2–20.

Michelson AD. Flow cytometry: A clinical test of platelet function. Blood 87 (1996) 4925–4936.

Provan D, Stasi R, Newland AC et al. International consensus report on the inves-tigation and management of primary immune thrombocytopenia. Blood 115 (2010) 168–186.

Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten: Faktor VIII-Konzentrate, Faktor VIII-/von Willebrand-Faktor-Konzentrate, Faktor IX-Konzentrate, Aktivierte Prothrombin-Komplex-Konzentrate. Hrsg.: Wissen-schaftlicher Beirat der Bundesärztekammer. S. 109–130, Deutscher Ärzteverlag, 2009.

Riess H. Aktiviertes Protein C bei Sepsis. Arzneimitteltherapie 21 (2003) 66–72.

Ruggeri ZM. Von Willebrand factor, platelets and endothelial cells. J Thromb Haemost 1 (2003) 1335–1342.

Sadler JE. A revised classifi cation of von Willebrand disease. Thromb Haemost 71 (1994) 520–525.



Schramm W, Barthels M. Faktor VIII-Konzentrate, Faktor VIII/von Willebrand-Faktor-Konzentrate, Faktor IX-Konzentrate, aktivierte Prothrombin-Komplex-Konzentrate. In: Vorstand und Wissenschaftlicher Beirat der Bundesärztekammer (Hrsg.). Leitlinien mit Blutkomponenten und Plasmaderivaten. Köln, Deutscher Ärzte-Verlag 2003. S. 117–141.

Stasi R, Evangelista ML, Stipa E et al. Idiopathic thrombocytopenic purpura: Cur-rent concepts in pathophysiology and management. Thromb Haemost 99 (2008) 4–13.

Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clinic Proc 106 (2004) 504–522.

Warren BL, Eid A, Singer P et al. High-dose antithrombin III in severe sepsis. JAMA 286 (2001) 1869–1878.

27 Thrombophilie, thrombembolische Erkrankungen und antithrombotische Therapie

Ansell J, Hirsh J, Poller L et al. The Pharmacology and management of the vitamin K antagonists. Chest 126 (2004) 204S–233S.

Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous throm-boembolism in relation to clinical risk and thrombophilic risk factors: prospective cohort study. Lancet 362 (2003) 523–526.

Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med 351 (2004) 268–277.

Bauer KA. Management of thrombophilia. J Thromb Haemost 1 (2003) 1429–1434.

Coller BS. Anti GP IIb/IIIa drugs. Current strategies and future directions. Thromb Haemost 86 (2001) 427–443.

Den Heijer M, Rosendaal FR, Blom HJ et al. Hyperhomocysteinemia and venous thrombosis. A meta-analysis. Thromb Haemost 80 (1998) 874–877.

Ezekowitz MD, Falk RH. The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fi brillation. Mayo Clin Proc 79 (2004) 904–913.

Goldhaber SZ. Thrombolysis in pulmonary embolism. A debatable indication. Thromb Haemost 86 (2001) 444–451.

Gould MK, Dembitzer AD, Doyle RL et al. Low molecular weight heparins compa-red with unfractionated heparin for treatment of acute deep vein thrombosis. Ann Intern Med 130 (1999) 800–809.

Greinacher A. Heparin-induzierte Thrombozytopenie – Pathogenese und Behand-lung. Hämostaseologie 19 (1999) 1–12.

Hillarp A, Zöller B, Svensson P, Dahlbäck B. The 20.210 A allele of the prothrom-bin gene is a common risk factor among Swedish outpatients with verifi ed deep vein thrombosis. Thromb Haemost 78 (1997) 990–992.

e79


27 Thrombophilie, thrombembolische Erkrankungen

Hiller E. Cancer and thrombosis. Managing the risks and approaches to thrombo-prophylaxis. Onkologie 29 (2006) 474–478.

Hiller E. Venöse Thromboembolien bei Tumorerkrankungen. Arzneimitteltherapie 30 (2012) 177–184.

Hirsh D, Dalen J, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical eff ectiveness, and optimal therapeutic range. Chest 119 (2001) 8S–21S.

Kraaijenhagen RA, Anker PS, Koopman MMW et al. High plasma concentrations of factor VIIIc is a major risk factor for venous tromboembolism. Thromb Hae-most 83 (2000) 5–9.

Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 346 (2002) 752–763.

Lindhoff -Last E, Luxembourg B, Pabinger I. Update Thrombophilie. Haemostaseo-logie 28 (2008) 365–375.

Lubenow N, Greinacher A. Hirudin in heparin-induced thrombocytopenia. Semin Thromb Hemost 28 (2002) 431–438.

Middledorp S, Meinhardi JR, Koopman MMW et al. A prospective study of asym-ptomatic carriers of the factor V Leiden mutation to determine the incidence of ve-nous thromboembolism. Ann Intern Med 2135 (2001) 322–327.

Nowak G. New anticoagulants for secondary haemostasis. Anti IIa inhibitors. Hä-mostaseologie 29 (2009) 256–259.

Patscheke H. Thrombozytenaggregationshemmer. Hämostaseologie 23 (2003) 181–185.

Petzborn E. Factor Xa inhibitors. New anticoagulants for secondary hemostasis. Hämostaseologie 29 (2009) 260–267.

Schulz C, Mehilli J, Massberg S. Thrombozyteninhibition bei Koronarpatienten – etablierte und neue Substanzen. DBI der Bay Int 31 (2011) 30–37.

Turpie AG, Bauer KA, Eriksson BI et al. Fondaparinux vs. Enoxaparin for the pre-vention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Inter Med 162 (2002) 1833–1840.

Turpie AGG, Norris TM. Thromboprophylaxis in medical patients. The role of low-molecular weight heparin. Thromb Haemost 92 (2004) 3–12.

Völler H, Alban S, Westermann D. Neue orale Antikoagulanzien – Werden sie die Vitamin-K-Antagonisten verdrängen? Internist 51 (2010) 1571–1581.

Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis. Is there still an indica-tion? Thromb Haemost 86 (2001) 499–508.

E28 Literaturhinweise und Internetadressen - Elsevier.de · E28 Literaturhinweise und...

Documents

Transcript of E28 Literaturhinweise und Internetadressen - Elsevier.de · E28 Literaturhinweise und...